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ABBREVIATIONS 
 
AADC Amino acid decarboxylase  
AcOH Acetic acid  
AVG  Average 
Boc2O  Di-t-butyl dicarbonate 
BA Biological activity 
BTAC Benzyltriethylammonium chloride 
CDI 1,1'-Carbonyldiimidazole 
DBH  Dopamine hydroxylase 
DCC Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DIC  Diisopropylcarbodiimide  
DIPEA N,N-Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine  
DMC 2-Chloro-1,3-dimethylimidazolinium chloride 
DMF Dimethylformamide 
EDC•HCl N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride 
ESI Electrospray ionization 
EtOAc Ethyl acetate 
GPCR G-protein-coupled receptors 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
 hexafluorophosphate 
HOBt  Hydroxybenzotriazole 
HCV Hepatitis C virus 
Hex Hexane 
HRMS High resolution mass spectrometry 
IR  Infrared 
MIC Minimum inhibitory concentration  
NMR Nuclear magnetic resonance 
PheOH  Phenylalanine hydroxylase  
RSD Relatively standard deviation 
  
 
SAR Structure-activity relationship 
SD  Standard deviation 
SEM  Standard error of the mean 
SIM Selected-ion monitoring chromatogram 
p-TsCl 4-Toluenesulfonyl chloride 
TA Trace amine 
TAAR Trace amine-associated receptor 
TBAT  Tetrabutylammonium tribromide 
TEA Triethyl amine 
TFA Trifluoroacetic acid 
TLC Thin layer chromatography 
TOF Time of flight 
TyrOH Tyrosine hydroxylase 
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1 INTRODUCTION 
 
Natural products have always been an important source of medicines (Molinski et al. 
2009). In the last few decades every fourth drug approved to the market is a derivative 
from a nature product (Newman and Cragg 2012). Due to the limitations of underwater 
research the natural medicines used today are mostly from terrestrial plants and 
microbes, e.g. morphine, digitalis toxin (Molinski et al. 2009). However, due to the 
success stories in the marine discovery and enormous biodiversity of the sea, there is a 
growing interest for marine species exploration as novel lead compounds.  
  
Sponges are one of the most studied marine species (Gerwick and Moore 2012). The 
research of these primitive metazoans has already offered approved drugs and they 
remain to stay in important role partly due to their interesting role to live with symbiosis 
with microorganisms (Taylor et al 2007). Pseudoceratina purpurea is a sponge that 
belongs to Verondiga order (Tilvi et al 2004). Sponges from this order are known to be 
source of many novel isolated bromotyramines. Bromotyramines have shown biological 
activity and recently there have been efforts to synthesize these isolated 
bromotyramines in order to have sufficient amounts of pure compounds (Kottakota et 
al. 2012). This is crucial for proper biological activity evaluation. 
 
MAREX (2010-2014) was an EU funded international project which target was to 
explore the biodiversity of seas and offer novel marine-based lead compounds for 
European industries (MAREX 2015). Even though the actual MAREX project is now 
ended, this work can be considered as continuum of the project. 
 
 
2 MARINE PHARMACEUTICALS  
 
Unlike terrestrial products, marine organisms do not have a significant history of use in 
medicine (Cragg and Newman 2013). This might be surprising, since world's oceans 
covers more than 70% of the earth's surface and it represent an enormous resource for 
the discovery of potential medicines. One of the reasons for short history of marine 
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pharmaceuticals was limited and unreliable scuba diving techniques. Before their 
improvement about 45-50 years ago, the collection of marine organisms was limited to 
people able to skin-dive. When depths till approximately 40 m became routinely 
available, the discovery of marine compounds as novel bioactive compounds was able 
to begin. However, this was only a start. It is estimated, that over 95% of the sea area is 
deeper than 1 km and at the same time it is known that deep sea is one of the most 
biodiverse and species-rich areas on the planet, rivaling with coral reefs and rainforest 
(Skropeta and Wei 2014).  
 
2.1 The clinical pipeline 
 
Even though the marine exploration is far beyond ready, the clinical pipeline of marine 
derived compounds reveals some success already. Till the year 2010 there was only 
three marine based drugs approved by FDA and one EU registered drug (Mayer et al. 
2010). Total 13 marine natural products or their variations were in clinical pipeline and 
large amount in the preclinical pipeline. Four years later, 2014, the amount of FDA 
approved marine-derived compounds was six while there was only one EU registered 
marine drug (Mayer 2014). In 2014, there were two marine-derived compounds in 
phase III trials, six in phase II, three between the phase I/II and 14 in phase I trials. The 
total amount of marine-derived compounds in the clinical pipeline was 25 in June 2014. 
This means that the amount of marine-derived compounds in clinical pipeline has 
doubled in four years. In the last 20 years there have been more than 1 000 marine 
chemicals in the preclinical pipeline that have a large amount of miscellaneous 
mechanism of action. At the moment, the pipeline mainly consist novel anticancer 
agents but there are also compounds that have activity against inflammation and mental 
illnesses. Thus, there is a strong believe that the marine-derived compounds in the 
preclinical pipeline will provide new lead compounds to the marine clinical 
pharmaceutical pipeline (Mayer et al. 2013).  
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2.2 FDA and EU approved marine drug(s) 
 
The preclinical pipeline is strong and there are marine derived compounds in clinical 
pipeline that will most likely make their way to market (Gerwick and Moore 2012). 
However, there are already 6 marine compounds approved by FDA and one EU 
registered compound. The FDA approved marine drugs are cytarabine (Cytosar-U), 
vidarabine (Vira-A), ziconotide (Prialt), eribulin mesylate (Halaven), brentuximab 
vedontin (Adcetris) and omega-3-acid ethyl esters (Lovaza) (Figure 1). The EU 
registered drug is trabectedin (Yondelis).  
 
 
Figure 1. FDA approved and EU registered marine drug(s). Ziconotide is not included 
due to its complex structure. 
 
Cytarabine (Cytosar-U) was the first marine derived product that was approved by FDA 
in 1969 (Mayer et al. 2010). Cytarabine was originally isolated from the Caribbean 
sponge Tethya crypta and it inhibits DNA polymerase and DNA synthesis which causes 
apoptosis. It is primarily used for to cure leukemia's. Five years later, the next marine 
derived medicine vidarabine (Vira-A) was approved by FDA in 1976 (Mayer et al. 
2010). It is a synthetic purine nucleoside that was synthesized based on a molecule 
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found from the same Caribbean sponge Tethya crypta. In human, vidarabine inhibits 
DNA replication of viruses. Vidarabine's marketing status is currently discontinued, 
since better antiviral medicines have been developed. Both vidarabine and cytarabine 
have been remarkable medicines in the field of anticancer medication. After vidarabine 
was brought to the market, it took almost 30 years for the next approved marine based 
medicine.  
 
Ziconotide (Prialt) was approved by FDA 2004 (Cragg and Newman 2013). Ziconotide 
is a non-narcotic analgesic (Atanassoff et al. 2000). The compound was originally 
isolated from venom of cone snail genus Conus that stuns their prey prior to capture 
(Cragg and Newman 2013). Ziconotide is mainly used as last option since it has to be 
delivered via intrathecal injection route. The same year new marine based product 
containing omega-3-acid ethyl esters (Lovaza) was approved by FDA (Koski 2008). 
Lovaza is a prescription drug that contains high amount of DHA and EPA. It is made of 
fish purified fish oil and it is used to treat hypertriglyceridemia.  
 
Trabectedin (Yondelis) was approved in September, 2007, by EMEA for the treatment 
of soft tissue sarcomas (Cragg and Newman 2013). Trabectedin was originally isolated 
from a colonial tunicate Ecteinascidia turbinata and it as complex alkaloid. It is 
believed that complex structure of trabectedin allows it to bind to the guanines in the 
minor groove of the DNA double helix and thus cause apoptosis (Petek et al. 2015).  
 
Eribulin mesylate (Halaven) was approved 2010 by FDA (Cragg and Newman 2013). 
The compound is derived from halichondrin that can be found from different marine 
species including sponge Halichondria okadai and bryzoa Bugula neritina. Due to the 
complexity of the molecule the total synthesis was impractical for drug development 
(Doherty and Morris 2015). Fortunately, it was found that only a half of the molecule 
was demanded for the pharmacological effect. Brentuximab vedotin is an antibody drug 
conjugate that was approved by FDA 2011 (Cragg and Newman 2013). It was derived 
originally from marine mollusca (Mayer 2014). It consist three different components: a 
chimeric immunoglobulin specific for human CD30-antibody, microtubule disrupting 
agent MMAE and protease-cleavable covalent linker (Younes et al. 2012). The part 
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chimeric immunoglobulin is produced is Chinese hamster ovary cells and the small-
molecule parts are synthesized. Brentuximab vedotin is used e.g. against Hodgkin’s 
lymphoma. 
 
2.3 Marine pharmaceuticals future and challenges 
 
The approved drugs are important success stories in marine based drug discovery that 
brings confidence to the field of study. The efforts have not been useless: the rate of 
discovering a new medicine from all the marine compounds studied is approximately 
1.7- to 3.3-fold better than the industry average (Gerwick and Moore 2012). The 
promising results of marine field have inspired more researchers to find new interesting 
compounds from the sea.  
 
However, there are ethical issues that need to be considered (Cragg et al. 2012). The 
most accessible marine biodiversity and the majority of species are inside economic 
zones of countries. Thus, there is an organization United Nations Convention on 
Biological Diversity (CBD) that is establishing international manners in marine drug 
discovery. The objects in the CBD are to conserve the marine biodiversity, use 
components sustainably and to share the benefits arising out of the utilization of genetic 
resources. This serves the field of marine drug discovery and the collaboration between 
biodiversity-rich and scientifically-rich countries. The agreements made helps the 
researchers to explore the marine species.  
 
While the ethical issues and rules have been partly solved, there has also been 
development in the analytical methods (Gerwick and Moore 2012). Due to this, the 
needed amounts of the samples have become smaller. This helps to destroy marine 
biodiversity as little as possible. Also, it allows the exploration of marine species 
existing in very low biomass in nature, such as thinly encrusting invertebrates or micro 
algal slimes. Unfortunately, the small sample sizes have also downsides. Often, the 
amounts collected from the seas are enough for the identification but not for the 
biological activity evaluation. Thus, it is important to find synthesis routes to study the 
possible biomedical activity of novel compounds.  
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There are also cases were new interesting biological activity have been reported, but the 
research have not been continued. For instance, between the years 2009 and 2011 there 
were 230 reported compounds that showed biological activity (Mayer et al. 2013). 
There is a great need to proceed the research of these new compounds. One approach 
are projects where academic investigators are partnered with pharmaceutical companies 
and institutes such as National Cancer Institute’s (NCI) (Gerwick and Moore 2012). The 
programs have been successful providing new compounds that have gone to clinical 
trials.  
 
Even though marine species are still relatively poorly known, a large number of marine 
compounds in shallow water have been characterised (Gerwick and Moore 2012). Large 
marine species or the ones that are easy to access are becoming more and more familiar 
while the technology for exploring new compounds from deeper parts of the sea still 
needs to develop (Skropeta and Wei 2014). Thus, there has been a growing interest to 
explore small creatures such as marine bacteria and fungi that have been left out of 
attention (Gerwick and Moore 2012). It is now understood that a large number of new 
nature compounds that are isolated from macroorganisms, such as sponges, are actually 
metabolic products of microbes. Due to the estimation that only a percent of all bacteria 
presented in sea water is cultured, it is clear that there is a great potential for new lead 
compound discoveries from the sea. 
 
  
3 MARINE SPONGES 
 
Sponges (Porifera) are considered to the most primitive of metazoans (Taylor et al. 
2007). They arise at least from the Precambrian time 600 million years ago. The 
divergence of sponges from the other species may have happened even 1.3 billion years 
ago. Today, sponges are still well presented in the marine ecosystem covering up to 
80% of some shallow- and deep-water communities (Taylor et al. 2007; Skropeta and 
Wei 2014). There are over 8000 sponge species known to live in the shallow and the 
deepest parts of the seas. Sponges are the largest source of new marine natural products 
reported annually. The diagram visualizes the growing interest towards sponges and the 
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number of publications retrieved from SciFinder-database until the end of year 2014 
(Figure 2).  
 
 
Figure 2. Amount of publications found from SciFinder-database when the used search 
terms are *sponge* or *porifera*.  
 
3.1 Sponge morphology 
 
The environmental atmosphere for marine species is enormously different (Skropeta 
and Wei 2014). For instance, there are large variations in the pressure and temperature 
under water. In the deep parts of the sea, species needs to adjust their metabolism that 
they can function at depressed temperatures and high pressure. Needless to say, the 
organisms and sponges under sea level have to be adapted to their environment. 
 
Sponges can be divided in to three main classes by paraphyletic grouping: 
Hexactinellida (glass sponges), Calcarea (calcareous sponges) and Demospongiae 
(demosponges) (Borchiellini et al. 2001). Demospongiae contains the majority of extant 
sponges while Calcarea is a small group. The sponges of Hexactinellida group are 
mostly deep-water sponges. The discrepancy in sponges structure and tissue 
coordination is relatively small considering that they are one of the oldest multicellular 
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animals (Taylor et al. 2007). However, the morphology is otherwise highly diverse. 
There are sponges with different colors, shapes and sizes. The diameter of small 
sponges can be only few millimeters and the big sponges can be up to one meter.  
 
The morphology of sponges depends often on the surrounding area (Taylor et al. 2007). 
Sponges are sessile and they are efficient at obtaining food by filtering the nearby water. 
Thus, they need to adapt their function depending on the environment. Sponges living in 
the areas with short amount of food need to filter more water in order to get enough 
nutrients (Leys and Hill 2012). On the other hand, sponges living in the areas of high 
nutrient levels or in symbiosis with microbes need to process less water. It is estimated, 
that up to 24 000 liters of water can be pumped trough 1 kg sponge in a day (Taylor et 
al. 2007).  
 
With the large amount of water running through sponges, it is obvious that there are 
large amount of microorganisms and other particles going through sponges. Sponges 
have a capability to recognize different bacteria and microorganisms and discriminate 
the food they consume (Wilkinson et al. 1984). This may be due to protective capsular 
material of the symbiotic bacteria. The incapability to consume some type of bacteria 
can lead to high density of microorganism inside the sponge that can occupy up to 40% 
of the total sponge tissue volume (Taylor et al. 2007). The microorganisms that stay 
inside the sponge and can't be consumed as food can live in symbiosis with sponge. 
Some of the microorganisms can protect the sponge by expressing metabolic products 
that are not harmful for the sponge itself, but that protect it from other animals. On the 
other hand, microorganisms that only live inside the sponge but are not useful for the 
sponge are parasites. The realization of the importance of microorganisms in sponges 
have awakened the researchers that majority of the identified compounds may be 
metabolic products. In mature of fact, all three FDA approved medicines from sponges 
(cytarabine, vidarabine, eribulin mesylate) are predicted to be biosynthetic product of 
bacteria (Gerwick and Moore 2012).  
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3.2 Pseudoceratina purpurea 
 
Pseudoceratina purpurea is a widely dispersed sponge (World porifera database 2015). 
It can be found for instance from Indian Ocean and Pacific Ocean. Pseudoceratina 
purpurea can live in different depths and it have been collected from shallow water (-1 
m) and deeper parts of seas (-40 m) (Jurek et al. 1993; Gotsbacher and Karuso 2015). 
Even though -40 m was the deepest collection depth that was found from the literature, 
it is possible that the sponge can live even in deeper parts of seas.  
 
Pseudoceratina purpurea has often a dense collagen aggregations and sparse irregular 
dendritic fibers (Bergquist and Cook 2002). The reason why Pseudoceratina purpurea 
is an interesting sponge is that it is a major source of bromotyramines. Bromotyramines 
are a large group of molecules with various biological activity and new compounds are 
published constantly (Gotsbacher and Karuso 2015). Additionally, epibiotic 
microorganisms have been identified to live in symbiosis with Pseudoceratina purpurea 
that protects the sponge from pathogenic bacteria (Kanagasabhapathy and Nagata 
2008). 
 
The naming culture of sponges such as Pseudoceratina purpurea is diverse. This is 
understandable since the richness and diversity of marine species is fairly new subject. 
The naming of Pseudoceratina purpurea is covered more in other master's thesis work 
from University of Helsinki (Flemmich 2015). Pseudoceratina purpurea that belongs to 
Verondiga order of sponges was brought to general public in the late 19th century 
known as Pseudoceratina Carter (Bergquist 1995). During the years the same 
Pseudoceratina Carter-sponge was re-identified multiple times as a novel sponge specie 
and multiple names was given to the same sponge. An often used synonym for 
Pseudoceratina purpurea is Psammaplysilla purpurea but there are multiple other 
synonyms too (World porifera database 2015). Many of the bromotyramines covered in 
this thesis are originally isolated from Pseudoceratina purpurea. 
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4 BROMOTYRAMINES 
 
Tyramine 1 is a small amine compound that can be found in many organism e.g. plants, 
bacteria, insects and other invertebrates to mammals, including human (Scheme 1) 
(Branchek and Blackburn 2003). It is a trace amine (TA) that is chemically related to 
biogenic amines. Some of the TA's in mammals are tyramine 1, phenetylamine 2 and 
octopamine 3 that are metabolized from phenylalanine 4 (Branchek and Blackburn 
2003). TA's are believed to act as neurotransmitters or neuromodulators.  
 
Tyramine 1 is produced in the human body, but it is also ingested from food such as 
dairy products and wine (Ladero et al. 2009). In food supplements, 1 is produced by 
lactic acid bacteria which are crucial micro-organisms due to their food fermentation 
and their contribution of healthy homeostasis. In human body, 1 is metabolized from 
tyrosine 5 with amino acid decarboxylase (AADC) and through hydroxylation from 2 
(Scheme 1) (Hiroi et al. 1998). Tyramine 1 is metabolized to dopamine 6 by CYP2D6, 
but 1 can be metabolized through other routes too. For instance, 1 is a substrate for both 
monoamineoxidase A (MAO-A) and B (MAO-B) which catalyze the oxidation of 
monoamines (Hauptmann et al. 1996).  
 
Scheme 1. Biosynthesis of tyramine 1 in vivo 
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Tyramine 1 and other TAs are linked to psychiatric disorders like depression and 
schizophrenia (Lindeman et al. 2005). Their concentration in central nervous system is 
generally low but they are known to have pharmacological activity. Nowadays, they are 
also known to have specialized G-protein-coupled receptors (GPCR), trace amine-
associated receptor (TAARS) (Lindeman et al. 2005). Tyramine 1 displaces 
norepinephrine 7 from neuronal storage vehicles causing vasoconstriction and increased 
blood pressure through positive chronotropic effects (Shulman et al. 2013).  
 
4.1 Bromotyramines and their biological activity 
 
Bromotyramines are tyramine 1 derivatives where one or two hydrogens of the aromatic 
ring have been replaced by bromine. They are a large group of molecules that are 
mostly isolated from sponge Pseudoceratina purpurea. The molecule weight is more 
than doubled due to the atomic mass of bromine. The first marine bromotyramine 
derivative N,N,N-trimethyldibromotyramine 8 was indentified in 1978 from a sponge 
Verongia fistularis (Figure 3) (Peng et al. 2005).  
 
 
Figure 3. N,N,N-trimethyldibromotyramine 8 
 
The naming of bromotyramines in literature is confusing. Compounds that are identified 
from marine species, have some of the TA's (1, 5 etc.) in the molecule structure and 
contain bromine are generally called as bromotyrosines (Peng et al. 2005). Tyrosine 5 is 
only one metabolic step away from 1 (Scheme 1). From this perspective, it is 
understandable to use the common name bromotyrosines. After all, bromotyramines 
could be metabolized from bromotyrosines in sponges either by the sponge itself or by 
the microorganisms living in symbiosis with sponge. However, there are a large amount 
of publications from bromotyrosines and bromotyramines both identified from sponges. 
It is reasonable to keep these two kind of brominated TA's in separate classes and use 
the correct terminology. In this master's thesis, the focus will be in bromotyramines that 
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are halogenated from the tyramine 1 aromatic ring. Additionally, all the brominated 
TA's that have substituents in the ethyl chain between the amine and the 1 aromatic ring 
were dropped out. There is one exception in the end of the chapter. In the end of this 
chapter there is also a table that summarizes the biological activity of the compounds 
(Table 1). 
 
4.1.1 Bromotyramines isolated from Pseudoceratina purpurea 
 
 
 
Figure 4. Moloka'iamine 9, 3-bromo-5,6-dihydroxy-2-methoxybenzaldehyde 10 and 
ceratinamine 11 
 
Moloka'iamine 9 is often represented as a substructure for bromotyramines (Figure 4) 
(Hamann and Scheuer 1993). It was represented first time in 1993 from sponge that was 
most likely Pseudoceratina purpurea. Biological activity tests made in 1993 did not 
show potential antiviral, cytotoxic, immunomodulator or antifungal activity for 9. In the 
same tests, non-bromotyramine derivative aromatic aldehyde 3-bromo-5,6-dihydroxy-2-
methoxybenzaldehyde 10 isolated from the same sponge had cytotoxity with lower 
minimum inhibitory concentration (MIC). Additionally, 10 had antiviral activity with 
concentration 2 µg/ml while the needed concentration of 9 against the same cell line 
was >80 µg/ml. These results did not encourage to investigate the biological activity of 
9 more.  
 
 
Figure 5. Moloka'iakitamide 12 
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Couple years later after 9 was identified from Pseudoceratina purpurea, it was isolated 
again with its derivate ceratinamine 11 (Figure 4) (Tsukamoto et al. 1996). Tsukamoto's 
team (1996) made biological activity tests where 9 and 11 had both antifouling activity 
against Balanus amphitrite cyprid and cytotoxic against P388 murine leukemia cells. 
However, they did not show significant antifungal or antibacterial activity. Years later, 
9 was isolated from Red Sea sponge Pseudoceratina arabica with other bromotyramine 
related compounds (Badr et al. 2008). Moloka'iamine 9 with the new isolated 
bromotyramine, moloka'iakitamide 12, showed significant parasympatholytic effects on 
isolated rabbit heart and jejunum (Figure 5). The biological activity tests made by 
Badr's team (2008) showed weak antifungal activity for 12.  
 
 
Figure 6. Purpurealidin E 13 
 
Purpurealidin E 13 was originally identified in 1998 from Pseudoceratina purpurea 
collected from Mandapam coast, India as an unknown and acetylated salt (Figure 6) 
(Venkateswarlu et al. 1998). The counter ion of the identified compound was not 
determined. One year later, in 1999, 13 was characterized as its N-acetyl derivative 
(Rama Rao et al. 1999). Purpurealidin E 13 was identified again from the same sponge 
five years later (Tilvi et al. 2004). However, later it was discovered that the identified 
13 by Tilvi's team (2004) was probably a salt (Kottakota et al. 2008). Purpurealidin E 
13 was tested against multiple Gram-negative and Gram-positive bacteria, and two 
pathogenic yeasts (Kottakota et al. 2012). It didn't show any biological activity against 
any of the tested compounds. This correlates the poor biological activity seen with the 
similar compound 9 (Hamann and Scheuer 1993; Tsukamoto et al 1996). 
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Figure 7. JBIR-44 14 and aplysamine 4 15 
 
JBIR-44 14 and aplysamine 4 15 were both extracted from Pseudoceratina purpurea 
collected from Kinwan bay, Japan (Figure 7) (Fujiwara et al. 2009). Both of the isolated 
compounds were tested against human cervical carcinoma HeLa cells and their 
cytotoxity was screened. Approximately equally strong cytotoxic effect was noticed and 
there was no difference between the longer or the shorter alkyl chain attached to the 
phenolic oxygen. This suggests that the alkyl chain does not play role in the cytotoxity. 
On the other hand, this could suggest that the non-tyramine aromatic ring is more 
crucial for the cytotoxity. This idea is supported by the tests made by Hamann and 
Scheuer (1993), since the small aromatic aldehyde 10 had more cytotoxic than 9. 
 
 
Figure 8. Aplysamine 2 17 and aplysamine 3 16 
 
Aplysamine 4 15 was originally isolated in 1993 from Pseudoceratina purpurea (Jurek 
et al. 1993). It was collected by scuba on the south shore of Maui, Hawaii, at the depth 
of 40 m. It was identified with a bromotyramine salt that had three bromines instead of 
four. The compound is also known as aplysamine 3 16 (Figure 8). Jurek's team (1993) 
did not try to determine the counter ion of the salt. Aplysamine 2 17 was already found 
earlier and it was reported inactive in several tests against Gram-positive and Gram-
negative bacteria. However, test made by Jurek's team (1993) showed mild activity 
against Staphylococcus aureus for 16 and 15. No activity against Escherichia coli was 
observed. Compounds 17, 16 and 15 were found to be cytotoxic in mouse lymphoid 
neoplasm, human lung carcinoma, human colon adenocarcinoma and human oral 
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epidermoid carcinoma assays. They were also tested against HIV-1 assay but they didn't 
have significant antiviral activity. 
 
Purealidin Q 18, 16-debromoaplysamine-4 19, Purpuramine I 20 and a novel 
bromotyramine compound Purealidin B 21 were extracted from Pseudoceratina 
purpurea in 2004 (Figure 9) (Tilvi et al. 2004). The sponge was collected by scuba 
diving at a depth of 8–10 m from Mandapam, India. Purealidin Q 18, 21 and earlier 
identified purealidin P 22 have a heterocyclopentane formed from oxime, which makes 
the molecule more rigid (Kobayashi et al 1995). The antimicrobial and antifungal 
activity of the compounds identified by Tilvi's team (2004) was evaluated. The 
compounds (18, 19, 20, 21) did not show any activity against Klebsiella sp. 
Pseudomonas aeruginosa strains and the fungal strains. Purealidin Q 18 and 19 showed 
activity against Salmonella typhi. Purealidin B 21 showed good activity and 19 minor 
activity against Escherichia coli. Moderate activity against Staphylococcus aureus was 
confirmed for 20. It also showed moderate activity against Escherichia coli and Vibrio 
cholerae. Overall, the compounds were noticed to have from minor to good activity 
against several bacteria. Purealidin Q 18 and 22 were earlier noticed to have cytotoxity 
against murine lymphoma cells and human epidermoid carcinoma cells (Kobayashi et al 
1995). They have also showed inhibitory activity against epidermal growth factor 
(EGF) receptor kinase.  
 
Figure 9. Purealidin Q 18, purealidin B 21, purealidin P 22, 16-debromoaplysamine-4 
19 and purpuramine I 20 
 
16 
 
 
Two bromotyramine family grew by two in 2012 when purpurealidin J 23 and 
purpurealidin I 24 were indentified from Pseudoceratina purpurea as a part of MAREX 
project (Figure 10) (Tilvi and D'Souza 2012). The biological activity of the crude 
extract was tested in University of Helsinki. The average inhibitions of HCV replicon 
with the used concentration 100µg/ml were 24% (methanol) and 47% 
(methanol/chloroform) (Lillsunde KE, unpublished observation 2014).  
 
 
Figure 10. Purpurealidin I 24 and purpurealidin J 23 
 
4.1.2 Bromotyramines isolated from other sponges 
 
Even though Pseudoceratina purpurea  is one of the most important and studied 
sponges as a source of bromotyramines, there are other marine species where 
bromotyramines can be identified as well. Three halogenated tyramine derivatives 25, 
26, and 27 were identified from non-Verondiga sponge Iotrochorcl birotulata (Figure 
11) (Costantino et al. 1994). Identification of these novel compounds was interesting 
since bromotyramines or bromotyrosines were thought to be characteristic only for 
Verondiga family. Identification of these halogenated tyramines proved for the first 
time that bromotyramines can also be identified from other sponges.  
 
 
Figure 111. Bromotyramines 25, 26 and iodotyramine 27 isolated from Iotrochorcl 
birotulata 
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Aplyzanzine A 28 was originally found from sponge Aplysina sp (Figure 12) (Evan et 
al. 2001). It was collected from Indo-pacific Ocean close to the Zanzibar coast. At the 
same year two very similar compounds, suberedamine A 29 and suberedamine B 30, 
were identified from Okinawan marine sponge Suberea sp (Tsuda et al. 2001). Both of 
the sponges belong to Verondiga order. Tsuda's team (2001) made a narrow biological 
activity evaluation for 29 and 30. They were found to be cytotoxic against murine 
leukemia L1210 cells and epidermoid carcinoma cells. Both of the compounds showed 
antibacterial activity against Gram-positive bacteria Micrococcus luteus.  
 
 
Figure 12. Aplyzanzine A 28 and suberedamines A 29 and B 30 
 
These compounds were synthesized later, and new biological activity tests were made 
(Kottakota et al. 2012). The synthesis of 30 is discussed in chapter "4.3 Synthesis of 
bromotyramines" (p. 23). All three compounds 28, 29 and 30 were tested against Gram-
negative bacteria showing only mild activity. Against Gram-positive bacteria 
compounds 28, 29 and 30 had moderate activity. Aplyzanzine A 28 showed the most 
potent activity against Gram-positive bacteria and it also displayed moderate antifungal 
activity. Suberedamine B 30 showed cytotoxic activity against the NCI 60 cells and all 
the compounds had activity against Mycobacterium bovis and Mycobacterium 
tuberculosis. 
 
 
Figure 13. Dispyrin 31 and 4-bromo-N-[3-bromo-4-[2-(pyrrolidin-1-
yl)ethoxy]phenethyl]thiophene-2-carboxamide 32 
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Dispyrin 31 is a bromopyrrole tyramine that was identified in 2007 from a Caribbean 
sponge Agelas dispar (Figure 13) (Piña et al. 2007). Dispyrin 31 haven't shown any 
antibacterial or cytotoxic activity (Kennedy et al. 2008). However, it was found to be a 
potent ligand and antagonist of several therapeutically relevant GPCR including α1D and 
α2A adrenergic receptors and the H2 and H3 histamine receptors. Due to the potential 
nanomolar affinity for α-adrenergic receptors and low micromolar affinity for the H1 
and H3 histamine receptors, a number of analogues from the bromotyramine unit were 
synthesized (Kennedy et al. 2009). Functional groups into the pyrrolidine ring lowered 
the affinity for H3 receptors. Especially electron withdrawing fluorine had a large 
effect. A shortened alkyl chain also lowered the affinity, whereas altering the halogen 
atom from Br to Cl on the benzene ring had little effect. Also the heavy bromine 
halogen was noticed to be unnecessary for H3 inhibition. Alteration of heterocyclic 
pyrrole ring to tiophene lead to synthesis of 4-bromo-N-[3-bromo-4-[2-(pyrrolidin-1-
yl)ethoxy]phenethyl]thiophene-2-carboxamide 32 that increased the affinity to H3 
receptors and it produced analogues up to 33-fold higher affinity for inhibition of H3 
receptors compared to the natural product dispyrin 1. Many of the compounds with 
bromotyramine core noticed to be uniformly active in H3 inhibition.  
 
 
Figure 14. Aphrocallistin 33 
 
Aphrocallistin 33 was found from a sponge Aphrocallistes beatrix (Figure 14) (Wright 
et al. 2009). It was collected from Fort Pierce, Florida. Unlike most of the 
bromotyramines concentrated on this thesis, aphrocallistin has only a small acetyl 
substituent in the tyramine amine and a large purine in the phenol side of tyramine. The 
molecule was tested against Candida albicans, Pseudomonas aeruginosa, and 
methicillin-resistant Staphylococcous aureus and did not show significant inhibition. 
However, aphrocallistin showed cytotoxity against human tumor cells and it has been 
shown to induce cell cycle arrest in pancreatic carcinoma cells.  
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Figure 15. Bromopsammaplin A 34 
 
The focus in this thesis has been on bromotyramines without substituents between the 
tyramine aromatic ring and primary amine. Bromopsammaplin A 34 is an exception for 
this (Figure 15). It is a bromotyrosine that can be categorized to oxime-disulfides (Peng 
et al. 2005). It was originally isolated from two non-Verondiga sponge Pwrillartra sp. 
and Jaspis sp. (Park et al. 2003). Few years earlier a monobrominated analog of  
bromopsammaplin A 34 that was originally identified in 1995, had already shown 
antibacterial activity against methicillin resistant Staphylococcus aureus (Jung et al. 
1995; Kim et al. 1999). In the tests made by Park's team, 34 had even greater 
antimicrobial activity against some of the used strains of Staphylococcus aureus than 
the well-known antibiotic meropenem (Park et al. 2003). Additionally, it showed 
cytotoxity against the tested human tumor cell lines.  
 
Identification of bromotyramines 25, 26 and iodotyramine 27 was not only interesting 
due to the fact that they proved that bromotyramines can be identified from non-
Verondiga sponges. The other interesting finding was the presence of iodide. Even 
though iodide is a common mineral in the seas, it is relatively rarely seen in compounds 
identified from sponges (Peng et al. 2005). The finding suggested that iodization may 
depend on the capability of organism to concentrate iodide from seawater. Indeed, there 
has been observations that high concentrations of halogens correlates with the halogens 
found from the compounds (Costantino et al. 1994). It is possbile that there are high 
concentration of bromine inside the sponges where bromotyramines are identified. The 
concentrated amount of bromine could depend on sponges morphology. Another 
explanation could be, that tyramine derivatives are halogenated inside a microorganism. 
As discussed in chapter "3.1 Sponge morphology" (p. 7), microbes living in symbiosis 
with the sponges can be due to the incapability of sponge to consume the specific 
microbe as nutrition. There could be microbes that concentrates bromine and express 
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tyramine. This hypothesis would explain the small variations between the 
bromotyramines, since the metabolism of microbes is usually fast. 
 
Table 1. Biological activity of bromotyramine derivates 
Number Name of the compound Antiviral 
activity 
Antibacterial 
activity 
Antifungal 
activity 
Cytotoxity Miscellaneous 
activity 
24 
Purpurealidin I (Crude extract of 
pseudoceratina purpurea) 
X     
23 
Purpurealidin J (Crude extract of 
pseudoceratina purpurea) 
X     
18 Purealidin Q  X  X 
EGF receptor 
kinase inhibition 
29 Suberedamine A  X  X  
30 Suberedamine B  X  X  
34 Bromopsammaplin A  X  X  
28 Aplyzanzine A  X X   
21 Purealidin B  X    
19 16-Debromoaplysamine-4  X    
20 Purpuramine I  X    
15 Aplysamine 4  X  X  
16 Aplysamine 3  X  X  
17 Aplysamine 2    X  
9 Moloka'iamine   X X 
Parasympatholytic 
effects 
11 Ceratinamine   X X  
14 JBIR-44    X  
22 Purealidin P    X 
EGF receptor 
kinase inhibition 
33 Aphrocallistin    X  
12 Moloka'iakitamide   X  
Parasympatholytic 
effects 
31 Dispyrin     GPCR antagonist 
32 
4-bromo-N-[3-bromo-4-[2-
(pyrrolidin-1-yl)ethoxy]-
phenethyl]thiophene-2-
carboxamide 
    
H3 receptor 
inhibition 
13 Purpurealidin E      
 
4.2 Synthesis of purpurealidin E 
 
In this master's thesis, purpurealidin E 13 was used to synthesize novel bromotyramine 
derivates. It was one of the most important compounds in order to synthesize new 
bromotyramines. Thus, the synthesize of 13 is discussed in this separate chapter. 
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Purpurealidin E 13 was used 2005 to study a possible synthesis route for bromotyramine 
metabolites by using coumarin as a reagent (Harburn et al. 2005). Hardburn's team 
(2005) used purpurealidin E 13 as a starting material but did not report how they 
synthesized it. For the first time 13 was synthesized from tyramine 1 was in 2008 
(Scheme 2) (Yoshida and Yamaguchi 2008). 
 
 
Scheme 2. Synthesis of purpurealidin E 13 (Yoshida and Yamaguchi 2008)  
 
In the first step of synthesis a protective group (Boc) was attached to the primary amine 
of 1 giving the product 35 (Yoshida and Yamaguchi 2008). This is reasonable since the 
free electron pair of protected secondary amine is conjugated with the Boc-group. This 
prevents the formation of HBr-salt when is brominated. As source of bromine Yoshida 
and Yamaguchi (2009) used TBAT and the yield of bromination was relatively low 
(65%). In the third step t-butyl (3,5-dibromo-4-hydroxyphenethyl)carbamate 36 was 
treated with 3-dimethylamino-1-propanol 37 and the ether bond was formed. After the 
removal of protective group of 38, purpurealidin E 13 was formed. The overall yield 
was 39%. Yoshida and Yamaguchi (2008) did not offer any analytical data from 13, 
only from its acetylated derivative salt.  
 
Four years later, a new synthesis route for 13 was reported (Scheme 4) (Kottakota et al. 
2012). Kottakota's team (2012) used 1 as a starting material and the first two steps were 
made according to a recent publication (Scheme 3) (Kotoku et al. 2005). Kotoku's team 
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(2005) made the first two steps of the synthesis in different order than Yoshida and 
Yamaguchi (2008). First, 39 was synthesized by adding bromine and 1 in acidic 
conditions. In the second step a protective group (Boc) was added giving the product 
36. The overall yield of the first two steps was excellent (92%), especially if compared 
with the overall yield of the first two steps that Yoshida and Yamaguchi (2008) received 
(64%).  
 
 
Scheme 3. Synthesis of  36 (Kotoku et al. 2005) 
 
In the third step, 3-chloro-N,N-dimethylpropan-1-aminium chloride 40 was reacted with 
36 (Scheme 4). The reaction conditions and use of 40 by Kottakota's team (2012) 
offered little better yield (75%) compared to the yield of third step that Yoshida and 
Yamaguchi (2008) received (63%). In the last step the protective group of 38 was 
cleaved in acidic conditions giving the product 13 excellent yield (95%).  
 
 
Scheme 4. Synthesis of purpurealidin E 13 by Kottakota's team (2012)  
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4.3 Synthesis of bromotyramines 
 
Moloka'iamine 9 was synthesized in three steps as a reply to the growing interest 
against antifouling activity that bromotyramines had shown (Scheme 5) (Schoenfeld 
and Ganem 1998).  
 
 
Scheme 5. Synthesis of moloka'iamine 9 (Schoenfeld and Ganem 1998) 
 
The tin-containing antifouling paints used to prevent the growth of marine species on 
ship hulls were banned in 1987 in many western countries due to their toxicity to marine 
mammals. In the first step the protective group 2-(biphenyl-4-yl)propan-2-
yloxycarbonyl (Bpoc) was attached to the primary amine of 39 giving the product 41 
(Scheme 5). In the next step, 42 was synthesized when the phthalimide protected propyl 
chain was attached to the phenol. Finally the protective groups were cleaved in acidic 
conditions. The total yield for the final product was 50%.  
 
 
Scheme 6. Synthesis of bromotyramine derivate 43 with acyl chloride (Schoenfeld et al. 
2002) 
 
Acyl chlorides are well known to react with amines to form amide bonds. An example 
from this is a recent publication where a bromotyramine derivative with long alkyl 
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chain 43 was synthesized (Scheme 6) (Schoenfeld et al. 2002). A brominated tyramine 
with methylated hydroxyl group 44 was handeled with acyl chloride. The synthesis gave 
excellent yields (99%).  
 
 
Scheme 7. Total synthesis of moloka'iakitamide 12 (Yoshida and Yamaguchi 2009) 
 
Moloka'iakitamide 12 showed antifungal and parasymphatolytic activity reported by 
Badr's team (2008) and one year later the total synthesis was reported (Scheme 7) 
(Yoshida and Yamaguchi 2009). The used starting material was tyramine 1. The first 
two steps were made as shown in Scheme 2 (p. 21). In the third step a phthalimide 
protected 3-iodopropan-1-amine 45 was attached to phenolic oxygen of 36 to give the 
product 46. The protection of 45 amine was not necessary and there are examples in the 
literature where the reaction has been done without protective group (Scheme 2 and 4) 
(Yoshida and Yamaguchi 2008; Kottakota et al. 2012). In the next step phthalamite 
group was cleaved to give the product 47. In order to make a amide bond, 47 was 
handeled with oxamic acid 48 in the precense of 2-chloro-1,3-dimethylimidazolinium 
chloride (DMC). DMC is a strong dehydrating agent that can be used in amidation 
reactions instead of  dicyclohexylcarbodiimide (DCC) and  N-(3-dimethylaminopropyl)-
N-ethylcarbodiimide (EDC) (Isobe and Ishikawa 1999). Ultimately, TFA was used to 
cleave the Boc-group of 49 to give the product 12. The overall yield was 26%. 
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Scheme 8. Synthesis of suberedamine B 30 by using purpurealidin E as starting material 
(Kottakota et al. 2012). 
 
Aplyzanzine A 28 and suberedamines A 29 and B 30 were synthesized with a 
reasonable amidation reaction (Scheme 8) (Kottakota et al. 2012). For instance, 30 was 
synthesized by using 13 and carboxylic acid 50 as starting material. The used 
crosslinking agent for amidation reaction was EDC and hydroxybenzotriazole (HOBt) 
was used to activate the intermediate ester formed by the carboxylic acid. Since there 
was a protective group in 51, the final step of the reaction was to cleave it with TFA and 
the product 30 was formed. The solvent used in this specific reaction was THF, but the 
yields were similar with the amidation reactions done in CH2Cl2. The synthesis of 30 
was done with overall 72% yield. 
 
 
Scheme 9. Synthesis of dispyrin 31 (Kennedy et al. 2008). 
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The synthesis of 31 offers another interesting route for synthesis of bromotyramine 
derivatives (Scheme 9) (Kennedy et al. 2008). Unlike Kottakota's team (2012), 
Kennedy's group (2008) first step of synthesizing 31 was the amidation reaction 
between carboxylic acid 52 and methylated bromotyramine derivative 53. The used 
diisopropylcarbodiimide (DIC) is a crosslinking agent and HOBt was used to activate 
the intermediate ester. The amidation gave succesfully the product 54 with excellent 
yield (93%). In the second step the methoxy group was demethylated to hydroxyl with 
Lewis acid boron tribromide (BBr3) to form 55. The alkylation reaction was reported to 
be challenging from a reason that was not mentioned, but the use of N,N-dimethyl-3-
chloropropylamine 56 finally gave the desired product 31. The overall yield was good 
(68%). 
 
 
5 THE AIM OF THE THESIS 
 
The aim of this thesis was to synthesize new compounds by making amide bonds with 
the primary amine of purpurealidin E 13 and carboxylic acids. Carbodiimides, such as 
EDC, provide a versatile and well-known method to crosslink carboxylic acids and 
amines (Crosslinking Reagents Technical Handbook 2012). Amide bonds can also be 
synthesized with acyl chlorides. This master's thesis was continuum for the work done 
by other master's thesis student Paul Flemmich (Flemmich 2015). Flemmich 
synthesized successfully purpurealidin E 13.  
 
The crude extract of Pseudoceratina purpurea have shown potential activity against 
HCV (Lillsunde KE, unpublished observation 2014). HCV is a chronic virus disease 
that can ultimately cause cirrhosis and liver failure (Duodecim 2015). The treatment 
results of HCV have improved during the last years. Depending on the genotype of 
patient, HCV can be cured completely in some cases. However, the novel treatments do 
not accomplish to cure all the HCV infections. As a part of MAREX project, 
purpurealidin I 24 and J 23 were identified from the same crude extract that showed 
activity against HCV (Tilvi and D'Souza 2012). Thus, the aim was to design and 
synthesize novel compounds that were simplified analogs of 24 and 23 and test their 
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biological activity against HCV. Additionally, one goal of the thesis was to synthesize 
disulfide bromotyramine 57 that would mimic bromopsammaplin A 34.  
 
 
6 SYNTHESIS DESIGN 
  
The synthesis design of new bromotyramine derivatives was divided into two sections. 
First, purpurealidin E 13 needed to be synthesized. After the synthesis of 13, new 
bromotyramine derivatives were able to be synthesized through amidation reaction. In 
this chapter we will discuss the design of these routes.  
 
The synthesis of 13 was published recently (Scheme 2,3 and 4, p. 21-22) (Kottakota et 
al. 2012). The synthesis route published by Kottakota's team (2012) was repeated 
successfully in the University of Helsinki by master's thesis student Paul Flemmich 
(Flemmich 2015). This reaction route includes four simple steps and the yields of the 
reaction route have been moderate (Scheme 3 and 4) (Kottakota et al. 2012; Flemmich 
2015). In the first step, bromine will undergo electrophilic aromatic substitution reaction 
replacing two hydrogens from the tyramine aromatic ring. The addition of protective 
group (Boc) to the primary amine is necessary in order to prevent substitution to the 
amine in the third step. After the alkylation, the protective group can be cleaved.  
 
Scheme 10. Retrosynthetic route for bromotyramine derivatives  
 
After purpurealidin E 13, the amidation reactions to synthesize new bromotyramine 
derivatives were considered (Scheme 10). Amide bonds can be synthesized with 
multiple different reactions routes. For instance, Schotten–Baumann reaction is a well 
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known method to synthesize amides from acyl chlorides and primary amines (Scheme 
6, p. 23). The advantage of using acyl chlorides to form amide bonds is that the reaction 
is volatile and it usually gives excellent yields (Schoenfelds et al. 2002). The other 
advantage is that acyl chlorides can be formed from carboxylic acids. For instance, 
carboxylic acids will undergo a nucleophilic acyl substitution reaction with oxalyl and 
thionyl chloride. After the nucleophilic acyl substitution reaction the acyl can be reacted 
with primary amine. The disadvantage of this reaction is that oxalyl and thionyl 
chlorides are vulnerable and they react easily with the moisture of air which leads to 
hydroxylation of the carbonyl carbon. Thus, often they need to be distilled before using. 
 
 
Scheme 11. Reaction mechanism for bromotyramine derivatives using carbodiimide 
EDC to synthesize amide bonds 
 
Amides can also be formed with carbodiimide crosslinking agents (Scheme 11). EDC is 
a carbodiimide that is widely used reagent that forms an O-acylisourea intermediate. It 
reacts with the amine giving the desired amine product and urea. Bromotyramine 
derivatives have been successfully synthesized with carboimiides (Scheme 8 and 9, p. 
25) (Kennedy et al. 2008; Kottakota et al. 2012). Carbodiimides are more pleasant to 
handle than oxalyl and thionyl chloride. They are hygroscopic and vulnerable to 
moisture but less than oxalyl and thionyl chloride. The disadvantage is generally lower 
yields. The formed urea can be problematic to extract from the reaction mixture since 
purpurealidin E 13 has similar functionality (tertiary amine).  The amidation reactions 
were decided to be made by using acyl chlorides or the by use of carboiimides as 
crosslinking agents. 
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Figure 16. Carboxylic acids 58-70 that were chosen for the synthesis of bromotyramine 
derivatives 
 
Both amide synthesis methods can be done with commercially available carboxylic 
acids. Since the aim of the thesis was to synthesize new bromotyramine derivates that 
were meant to mimic purpurealidin J 23, it was reasonable to choose aromatic 
carboxylic acids. However, 23 is a relatively big and its isoxazole ring is attached to a 
non-aromatic cyclohexene with two bromine substituents and a methoxy group (Figure 
10, p. 16). The molecular weight is over 700 g/mol which is not favorable in medicinal 
chemistry when considered the Lipinski's rule of 5. Additionally, the molecule is 
complex to synthesize since the heterocyclic isoxazole is attached direct to the 
cyclohexene. In the joint of two cyclic groups there is a chiralic carbon and thus 23 has 
an enantiomer. If the isoxazole ring is dropped out from the structure, the cyclic hexene 
is attached straight to the carbonyl carbon and the molecule is simpler. Thus, the chosen 
carboxylic acids were simple aromatic carboxylic acids 58-70 (Figure 16). These 
carboxylic acids are structurally close to each others, since the possible differences in 
biological activity (BA) would offer important information from the possible binding 
site and structure-activity relationship (SAR). The aromatic rings have different 
halogens (F, Cl, Br) since they have a large impact to the molecule weight. Halogens 
have also different steric properties due to the differences in the size of electron clouds. 
These properties may show alternate behavior in the BA evaluation.  
 
30 
 
 
 
Scheme 12. Planned route for disulfide bromotyramine 57 derivative  
 
Bromopsammaplin A 34 has shown interesting antimicrobial activity with lower MIC 
values than meropenem against some Staphylococcus aureus strains (Figure 15, p. 18) 
(Park et al. 2003). Thus, a synthetic route was designed for disulfide bromotyramine 
derivative 3,3'-disulfanediylbis[N-[3,5-dibromo-4-[3-dimethylamino)propoxy]-
phenethyl]propanamide] 57 (Scheme 12). The synthesis was planned to start from the 
protection of 3-mercaptopropionic 71 thiol group. The thiol group of unprotected 71 
could react with primary amine of 13 forming an unwanted thioether side product. Easy 
method to protect the thiol group is to let it react with acyl chloride giving 3-
(acetylthio)propanoic acid 72 (Larsson and Ramström 2006). After protecting the thiol 
group, the amide bond can be formed between 13 and 72 by using carbodiimide giving 
the product S-[3-[[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]amino]-3-
oxopropyl] ethanethioate 73 (Kang  et al.  2014). After synthesizing 73 the acetyl group 
could be removed with acid catalyzed reaction giving a bromotyramine with free thiol 
group N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-3-
mercaptopropanamide 74 (Kang et al.  2014). Finally, the sulfur bridge can be 
synthesized with a method published recently giving the product 57 (Leino and 
Lönnqvist 2004)  
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7 RESULTS AND DISCUSSION 
 
7.1 Purpurealidin E  
 
7.1.1 Synthesis of purpurealidin E 
 
 
Scheme 13. Synthesis of purpurealidin E 13 
 
Purpurealidin E 13 was successfully synthesized three times with the overall yields 
35%, 30% and 29% (Scheme 13). The three separate times are indicated with alphabets 
a, b and c. The synthesis of 13 started from the bromination of tyramine. In the first two 
times the starting material was a HCl-salt of 1. When the first step was made for the 
first time 39a did not show satisfying bromination with the used ratio of bromine in the 
beginning. Even though the reaction was left overnight, TLC did not indicate 
dibromination. Thus, more bromine was added and the total amount of bromine in the 
end of reaction was 3.5 eq. The yield was still relatively low, only 69%. The second 
time this step was proceeded extra bromine was added again and the total amount of 
used bromine the reaction was 5.5 eq. The product 39b was filtrated and the yield was 
poor (24%). The poor yield was mainly due to insufficient filtration, since there was a 
lot of product in the filtrate solvent that crystallized after couple days. The crystals were 
filtrated again giving a total yield 79% for 39b. The third time 1 was brominated, the 
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used solvent was only AcOH. In the first two times there was water as co-solvent, but 
according to the literature this was not necessary (Kotoku et al. 2005; Wada et al. 
2011). Also, the used starting material was a molecule form of tyramine 1, not an HCl-
salt. The reaction was left overnight. The next day TLC indicated that the reaction was 
completed even though the used amount of bromine was lower than in the second time 
(3.5 eq). The brominated tyramine 39c was filtered with a sinter giving now a good 
yield (91%). 
 
In the next step a protective Boc-group was added. In all the three times the reaction 
was left overnight and the TLC indicated full completion of reaction. The yields were 
excellent. However, there was color variations between the reactions done and products 
received. In the first time, the product 36a was off-white solid (96%). In the second 
time, after TEA was added, the color of the reaction solvent turned black. After the 
extraction the received product 36b was dark green (94%). In the third time, the 
received solid 36c was mainly white but there were light brown areas amongst the white 
solid. The product 36c was purified with flash chromatography. There was light brown 
polar impurity that stayed in the top of silica column. The product 36c was now white 
homogenous solid and the yield stayed relatively good (83%). Thus, the purification 
with flash chromatography after the second step was a good method to remove the 
gummy impurity. 
 
The third step was the addition of 3-chloro-N,N-dimethylpropan-1-aminium chloride 40. 
The first time the reaction was made, after the work-up the received product 38a was an 
oil. The 
1
H-NMR-spectrum showed impurities. Due to this, the product was 
recrystallized. During the reflux dark solid/gum appeared to the bottom of the flask. It 
was assumed to be impurity and the flask was changed leaving the impurity to the old 
flask. The product 38a was white solid. The second time this step was performed, after 
adding all the reagents to the flask to color of the solvent was dark brown. In the 
extraction and washing procedure there was no separation between the layers. The 
product 38b was first brown oil, but after keeping the product in oil pump for 11 hr the 
product was hard dark brown solid. Again, the product was recrystallized and the 
received product 38b was light yellow. It seemed that there was impurity that was able 
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to be removed by recrystallization. The third time this step was made, the starting 
material 36c had already been purified with flash chromatography. The reaction solvent 
was light yellow. The work-up including the washing procedure was performed easily 
and no difficulties in phase separation appeared. The product 38c was off-white solid 
and the yield was 74%. The yields were moderate but they correlate, especially the third 
time, with the literature (Kottakota et al. 2012).  
 
The removal of protective Boc-group was the final step of the synthesis. The first time 
this final step was performed a miscalculation was made and the amount of added TFA 
was 70 eq when the right amount of TFA would have been 6 eq. However, yellow oily 
product 13a was received with yield 80%. The second time, this step was performed the 
correct amount of TFA (6 eq) was added. However, 
1
H-NMR-spectrum and TLC from 
the product indicated that the reaction wasn't completed and there was still starting 
material left. The amount of used TFA was same and the reaction time was longer 
compared to literature but from some reason the reaction was not finished (Kottakota et 
al. 2012). Due to this the reaction was made again. TFA was added in two batches and 
the total amount was 40 eq. Now the yellow oily product 13b was received with yield 
63%. The third time this final step was performed the added amount of TFA was 
straight 40 eq. The reaction was left overnight and washed with high amount of NaOH. 
The product 13c was again yellow oil and the yield was 53%. The yield was low for 13c 
probably due to insufficient work-up. 
 
In the first time purpurealidin E was synthesized, the total amount of used TFA was 
highly excessive (70 eq). Fortunately, it did not damage the final product. Theoretically, 
there was a possibility for ether cleavage through SN2 and nucleophilic substitution of 
H2O but since the reaction was made with anhydrous solvent under argon this did not 
occur. However, it is unclear why wasn't the amount of TFA (6 eq) used in the second 
time enough to cleave the Boc-group since in the literature, 1.2 eq was enough to detach 
the protective group with excellent yield (Kottakota et al. 2012). One possibility could 
be that the used TFA was not currant. The big amounts of used TFA caused problems in 
the extraction of the product. Even though careful washing procedure a small amount of 
TFA was probably left amongst the product in 13c since there was an extra peak seen 
34 
 
 
on 
13
C-NMR-spectrum. The final step and the removal of protective group should be 
repeated in heated conditions and the used amount of TFA should be lower. This would 
reduce the problems in extraction caused by to the acidity. 
 
7.1.2 Characterisation of purpurealidin E 
 
The 
1
H-NMR-spectra of synthesized 13a-c were all similar. However, the FTIR-
spectrum showed difference in the values 3200-3500. This area is characteristic for 
amines. A free amine should show broad peak with value 3500 when the protonated 
amine shows broad peak in the value 3030. The free amine peak of 13a seen in FTIR 
was obvious. However, there was no proper free amine peak seen for 13b in the FTIR-
spctrum and there was a reason to doubt that the amine of 13b was protonated.  
 
Thus, a cation exchange was made with ISOLUTE SCX-2-ion exchange column. 
1
H-
NMR or the FTIR did not show any changes for 13b after the cation exchange 
suggesting that the product 13b was not a salt. To confirm this information, the "cation 
exchanged" purpurealidin E was dissolved in 4 M HCl dioxane and the 13b HCl-salt 
was filtered. The result is compared in the table (Table 2). Kottakota's team (2012) had 
noticed before that the NMR-data of Tilvi's team (2004) published earlier was most 
likely from salt form of purpurealidin E 13.  
 
There is no clear correlation with either of the articles published (Table 2). One 
possibility that could explain the different values is that 13b HCl-salt was protonated 
from both primary and tertiary amine. The fact that hydrogens attached to the carbon 1 
and 11 have both high ppm values supports this idea. Also, the ppm values of -N(CH3)2 
are relatively similar with the results reported by Tilvi's team (2004). Surprisingly, the 
FTIR-spectrum for 13b HCl-salt shows a wide peak with value 3370. This argues with 
the data known that the protonated salt should be seen with value 3000. Also, since the 
peak of the 13b HCl-salt was more similar with 13a than with the molecule form 13b, 
it can be thought that it was more likely that 13a was a salt. However, since the NMR-
data was so similar in all the three purpurealidin E 13a-c synthesized, this is not likely. 
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Table 2. NMR-data of 13b HCl-salt compared with the literature 
 
 H-NMR δ (CD3OD) C-NMR δ (CD3OD) 
Positi
on 
13b HCl-
salt Tilvi et al. 2004 
Kottakota et al. 
2012 
13b HCl-
salt 
Tilvi et al. 
2004 
Kottakota et al. 
2012 
1 3.52 (m) 
2.73 (t, 13.2 Hz, 
6.6 Hz) 
2.86 (t, 7.3 Hz) 41.40 40.0 44.0 
2 2.93 (m) 3.24 (t) 2.70 (t, 7.3 Hz) 33.11 33.6 38.8 
3 
   
137.73 130.3 140.5 
4 7.58 (s) 7.43 (s) 7.43 (s) 134.46 133.0 134.3 
5 
   
119.31 117.3 119.2 
6 
   
153.02 150.7 152.9 
7 
   
119.31 117.3 119.2 
8 7.58 (s) 7.43 (s) 7.43 (s) 134.46 133.0 134.3 
9 
4.14 (t, 5.6 
Hz) 
4.05 (t, 5.6 Hz) 4.03 (t, 6.2 Hz) 71.14 69.8 72.8 
10 2.31 (m) 2.23 (m) 2.07 (m) 26.41 25.0 29.1                                             
11 3.18 (m) 2.44 (t, 5.6 Hz) 2.64 (t, 5.7 Hz) 57.00 55.8 57.6 
12 2.97 (s) 2.90 (s) 2.28 (s) 43.70 42.7 45.9 
13 2.97 (s) 2.90 (s) 2.28 (s) 43.70 42.7 45.9 
 
After the first synthesis of 13a a small amount was purified with flash chromatography 
to receive a MS-spectrum. Purpurealidin E 13 has earlier shown interesting pseudo 
molecular ion peaks and this case was no different (Table 3) (Tilvi et al. 2004). The 
MS-spectrum (SIM/ESI) showed two peaks with different retention times, 0.25 and 0.50 
for 13a. The ratio of the peaks area is almost 1:1. Calculated mass value of 13 is 
379.0021 and the two peaks had values 379.0024 and 379.0003. The peaks have almost 
identical MS-spectra with similar isotope pattern. Theoretically, it is not possible to 
have 0.0021 difference in the mass. However, there was a clear separation in the HPLC-
retention times suggesting that there might two different compounds. One explanation 
for the different retention times could be that a part of the product 13a was still a salt. 
However, this is idea is not supported by the FTIR-spectrum where there was a wide 
peak with value 3393 nor by the 
1
H-NMR-spectrum, since they both suggest that 13a 
wasn't a salt. Other possibility is that the formic acid used as co-solvent in the HPLC 
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formed a salt with 13a. The counter ion could have been detached and the measured 
mass ended up being almost identical with two different retention times.  
 
To study the pseudo molecular peaks more, MS-spectra were taken from 13b, "cation 
exchanged" 13b and 13b HCl-salt (Table 3). However, the spectra were now even more 
complicated. In all three spectra there were now even more pseudo molecular peaks. 
The difference 42 in mass value might be due to possible acetonitrile adduct since it was 
used as eluent.  
 
Table 3. The TOF MS/ESI pattern that represents the result from 13b, "cation 
exchanged" 13b and 13b HCl-salt. The difference between calculated value and 
received value with the possible peak explanation  
 
Calculated value for 13 is 379.0021 (Due to the isotope pattern for bromine the values in the 
picture are +2). The peaks on the right side do not origin from the compound. 
Pseudo molecular 
peak 
purpurealidin E 
peak 
Pseudo molecular peak - 
purpurelidin E 
Possible peak 
476 381 95 Unknown 
372 381 -9 Unknown 
423 381 42 
Acetonitrile 
adduct? 
408 381 27 Unknown 
 
Due to the possibility that 13 makes adducts with the used HPLC co-solvents, a direct 
mass without HPLC was taken (Picture 17). The major mass peak was now 379 but the 
peak 421 with difference 42 could still be seen. This argues with the claim that 421 is an 
acetonitrile adduct. However, MS-pattern was now clearer and most of the pseudo 
molecular peaks were not seen. This suggests that the "impurity" peaks are not actually 
impurities. More likely, the peaks are due to breakdown of 13 and reformation of the 
breakdown pieces. This can be also explained by two observations. First of all, there 
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would have been more impurities seen in the NMR-results if all the peaks seen in MS-
spectra are due to impurities. Secondly, since the yields of crude products after the 
crosslinking reactions were up to 85%, the starting materials 13a and 13b had to be 
quite pure.  
 
 
Picture 1. The MS-spectrum of 13 HCl-salt without chromatography. 
 
Tilvi's team (2004) reported that the isolated purpurealidin E 13 from Psammaplysilla 
purpurea was colorless oil. This oil was noticed to be most likely a salt later on 
(Kottakota et al. 2012). The synthesized purpurealidin E 13 was an orange gum reported 
by Kottakota's team (2012) similar than in this work. Similar compounds 
moloka’iamine 9 and moloka’iakitamide 12 reported by Hamann and Scheuer (1993) 
and Badr's team (2008) were white solids. Thus, the color and composition of pure 
purpurealidin E 13 is still unclear. Purpurealidin E 13 does not have any extended 
conjugations that could explain the orange color. Since the isolated salt of 13 by Tilvi's 
team (2004) was colorless oil, it is possible that the orange color is due to the synthesis 
procedure. It would be useful to purify 13 more or try alternate reaction routes and 
reagents in order to find out the composition of pure 13.  
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7.2 Carboxylic acids 
 
To synthesize bromotyramine derivatives it was necessary to synthesize some of the 
carboxylic acids that were not commercially available. The total synthesis of 3,5-
dibromo-4-methoxybenzoic acid 60 using 4-hydroxybenzoic acid 75 as starting material 
was succeeded in total three steps (Scheme 14).  
 
 
Scheme 14. Synthesis of 3,5-dibromo-4-Methoxybenzoic acid 60 
 
In the first step 75 was brominated. The mechanism and the reaction conditions were 
same than when 39a was synthesized (Scheme 13, p. 31). The product 62 was white 
solid and the yield was 78%. The last two steps were made twice. In the second step of 
the reaction methyliodide was added and the used solvent was DMF. Methyliodide is an 
easy target for nucleophilic attacks and it is used in substitution reactions since iodide is 
cleaved easily from the methyl group. Thus, both of the hydroxyl groups were 
methylated giving the products 76a and 76b. The yields were 71% and 75% and the 
product was white powder in both times. In the last step of the reaction lithium 
hydroxide was used to cleave the methoxy group and white solid carboxylic acids 60a 
and 60b were formed. The overall yields of the reaction were 47% and 51%. 
 
Since 4-methoxybenzoic acid 63 is commercially available, it was tried to be 
brominated and the synthesis of 60 would have been done in one step (Scheme 15). This 
reaction was not found from the literature. The reaction conditions were similar than in 
the synthesis step of 62 (Scheme 14). Excessive amount of bromine was added to the 
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reaction solvent. The product 61 was surprisingly a monobromine with low yield 29% 
(Scheme 15). 
 
Scheme 15. The monobromation of 63 giving the product 61 
 
The synthesis of monobromine 61 was surprising when the chemistry of aromatic 
hydroxyl, carboxyl acid and methoxy is considered. Aromatic carboxyl acid is 
moderately deactivating substituent since it withdraws the electrons from the aromatic 
ring and it directs substituents to meta position. Vice versa, hydroxyl and methoxy are 
strongly activating substituents that donate electrons to the aromatic ring and thus they 
are ortho-para directing. Halogens are weakly deactivating substituents that direct 
electrophiles to ortho-para positions. When the first bromine is attached to aromatic 
ring, it prevents the substitution of second bromine to the aromatic ring. The directive 
effect of aromatic hydroxyl and carboxylic acid overrules the monobromines preventive 
effect and the ring is dibrominated. From some reason this was not the case with 63 and 
the attached bromine overrules the ring activating effect of methoxy and the ring 
deactivating effect of carboxylic acid. 
 
7.3 Bromotyramine derivates 
 
The amidation reactions between purpurealidin E 13 and carboxylic acids 58-70 were 
started by the synthesis of bromotyramine derivatives 77 and 78 (Figure 17). In 77 the 
used carboxylic acid was 62 and to synthesize 78 the used acid was 64. The used 
reagents were EDC as cross-linking agent, DIPEA and the solvent was DMF.  
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Figure 17. Bromotyramine derivatives 77 and 78 
 
Even though both of the reactions were completed according to TLC, there were no 
products received. In the case of 77 the product couldn't be extracted. The problems to 
extract 77 with organic and water phase was due to the zwitterion functionality seen for 
tertiary amine and phenolic hydroxyl group. The pKA values of protonated tertiary 
amine and phenolic hydroxyl groups are approximately 10. This means, that it is not 
possible to have a pH where majority of molecule is free of charge. Thus, 77 was most 
likely trapped to the water phase when the product was extracted.  In the case of 78 the 
product was lost when it was tried to be purified with flash chromatography. 
 
 
Scheme 16. Synthesis of bromotyramine derivatives (general procedure 1) and the used 
carboxylic acids 
 
After the failed synthesis of 77 and 78 the crosslinking amidation reaction was 
optimized and general procedure 1 was made (Scheme 16). The details of the general 
procedure are told in the experimental chapter (p. 61). Kottakota's team (2012) 
published recently a reasonable amidation procedure with crosslinking agent EDC 
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(Scheme 8, p. 25). Even though DMF was most probably a suitable solvent for 
amidation reaction of 77 and 78, DCM was used as the reaction solvent due to the lower 
boiling point and easier evaporation. The weak nucleophilic base DIPEA was changed 
to similar base DMAP in the general procedure 1 due to a recently published article that 
showed reasonable yields (Morkunas et al. 2012).  
 
The synthesis of bromotyramine derivatives using the chosen carboxylic acids 58-70 
and purpurealidin E 13 as starting material was succeeded with the general procedure 1 
(Scheme 8). Total amount of 11 bromotyramine derivatives were synthesized and their 
compositions were identified by 
1
H-NMR (Figure 18).  
 
 
Figure 18. 11 new bromotyramine derivatives 79-89. The yields are from the crude 
products 
 
Based on the yields, reaction optimization and different ratios of reagents were tried 
during the work. However, there were quite large variations between the yields of crude 
products (Figure 18). The yields remained also relatively low compared to the literature 
(Kennedy et al. 2008; Kottakota et al.2012). However, the yields are only estimations 
since the amount of impurity may vary and it is not known. It would be useful to 
continue the optimization of general procedure 1. For instance, in this work DMAP was 
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used as poor nucleophilic base even though the role of DMAP is often to catalyze the 
amidation reaction with small equivalence (Neises and Steglich 1978). The use of base 
is essential since only deprotonated acids can attack as a nucleophile to the 
carbodiimide carbon. However, the reaction conditions should not be too basic, since 
EDC is noticed to work best in mildly acidic conditions (Crosslinking Reagents 
Technical Handbook 2012). The amount of used DMAP varied from 1.3 eq to 1.5 eq. 
Instead of using DMAP as the "main base", it would be useful to try to use DIPEA as 
poor nucleophilic base and add only small amount of DMAP to catalyze the reaction.  
 
In the synthesis of 79, the amidation reaction between 58 and 13 was done by using 
different crosslinking agent HBTU. Otherwise the reaction conditions were similar than 
in general procedure 1 (Scheme 16). The yield of the crude product was similar than 
with the reactions done with EDC, 75%. There were no advantages noticed in the use of 
HBTU instead of EDC. Thus, the use of EDC as crosslinking agent was continued in 
latter amidation reactions. However, in the literature there are other crosslinking agents 
than EDC and HBTU that haven given excellent yields of amidation reactions (Kennedy 
et al. 2008). Thus, it would be useful to test alternate crosslinking agents. Additionally, 
small amounts of HOBt could be added to the reaction to improve the yields. 
 
 
Scheme 17. Possible synthesis route for bromotyramine derivatives 
 
The reaction route and order could be changed (Scheme 17). The first step of synthesis 
of 31 done by Kennedy's team (2008) was the amide formation (Scheme 9, p. 25). The 
reaction gave excellent yields considering that it was a crosslinking reaction. There are 
many advantages in this reaction route. For instance, as a first step a large amount of 1 
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could be brominated (Sheme 17). In the second step brominated tyramine 39 could be 
reacted with the desired carboxylic acid and the amide bond could be formed with large 
scale (Mahindroo et al. 2009). Thus, a bromotyramine derivative could be formed only 
in two steps. After this, in the third step the aminopropyl chain could be attached by 
using 40 and the desired bromotyramine derivative could be formed. The amount of the 
reaction steps could be reduced in this way. Additionally, the amidation reaction could 
be done with larger scale and it could be optimized since the starting materials would be 
faster to make. 
 
 
Scheme 18. The designed synthesis route for acyl chlorides did not work 
 
The other designed route to synthesize amides was to use acyl chlorides (Scheme 18). 
Thus, bromotyramine derivate 81 was tried to be synthesized by using 60 and 13 as 
starting materials. The carboxylic acid 60 was first acetylated with oxalyl or thionyl 
chloride. A small amount of DMF was added to catalyze the reaction. After a while, 60 
was assumed to be converted to acyl chloride. Purpurealidin E 13 was added with TEA 
and the reaction was left over the weekend. The synthesis of 81 by using oxalyl or 
thionyl chloride surprisingly failed. It is possible, that oxalyl and thionyl chloride had 
been in touch with moisture. The synthesis of 83 was done successfully by using 13 and 
commercially available 4-methoxybenzoyl chloride 90 as starting material (Scheme 19). 
The reaction conditions were similar. THF was used as solvent and TEA was added as a 
reagent. The product was able to be synthesized and the yield of the crude product was 
50%. Unfortunately, the yield after purification of 83 was only 6%. However, 
successfull reaction of 83 suggests that the reason for failed reactions with oxalyl and 
thionyl chloride were mostly due to bad reagents. 
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Scheme 19. Synthesis of 83 by using 90 and 13 as starting material 
 
Three of the 11 novel bromotyramines were able to be purified (Figure 19). Two of the 
molecules, 84 and 81 were successfully recrystallized. One of the compounds, 82 was 
successfully crystallized as HCl-salt, 82 HCl-salt. Considering that the 
recrystallizations were done with small amount of product, less than 100 mg, the yields 
were satisfying. The biological activity evaluation was made for all the three 
compounds with a 13b HCl-salt. The results are discussed in chapter 7.6 (p. 48). 
 
 
Figure 19. Novel bromotyramines 84, 81 and 82 HCl-salt with overall yields 
 
7.4 Purification of bromotyramines 
 
Purification of the novel bromotyramines was one of the challenges faced in the work. 
When 78 was tried to be purified with automated flash chromatography, the product 
was lost in the column. Thus, the flash chromatography was considered to unsuitable 
purification method and an effort was made to find and optimize a suitable 
recrystallization solvent and procedure. One of the first recrystallizations that were 
made was successful and the product 80 was filtered as white solid. Even though the 
MS-spectrum of 80 did not suggest that the compound was pure, recrystallization was 
considered to be a suitable purification method.  
 
All the crude products were orange gummy oils, which made the recrystallization 
challenging. The hypothesis was that the orange gum was polar impurity that was 
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implemented to 13 maybe as early as in the second or first step of its synthesis (Scheme 
13, p. 31). This impurity seemed to bind efficiently the product. This was problematic, 
since the recrystallization solvent needed to be enough polar to dissolve the orange 
gum. If the gum did not dissolve, the amount of the product was too small in the solvent 
to be crystallized. On the other hand, if the used solvent was too polar and all the orange 
gum dissolved, the product never crystallized. A large number of solvents and solvent 
mixtures were tested including: hexane, 2-propanol, methanol, acetone, 
hexane/methanol, hexane/DCM, hexane/toluene and hexane/2-propanol. In the mixtures 
a small amount of hexane was added to the crude product and the heated to reflux. 
Hexane and drops of more polar co-solvent were added till the most of the gum was 
dissolved. This method led to a successful recrystallization two times giving the pure 
products 84 and 81. The used solvents were hexane with drops of methanol or DCM. 
These used solvents failed in many other recrystallizations that was tried to be made. 
This provokes an interesting question: Why did the recrystallization happen for 84 and 
81 but not for the other pure compounds? One explanation could be the molecule 
weight. 84 and 81 are both dihalogenated from the "non-tyramine" aromatic ring. High 
molecule weights tend to increase the melting point and thus the solid could be more 
easily achieved.  
 
Due to the complicate recrystallization, 87 and 86 were tried to be purified with manual 
flash chromatography regardless of the challenges faced when 78 was tried to be 
purified. If the hypothesis from the impurity was right, the polar orange gum should 
have stayed in the stationary phase. Indeed, when 87 and 86 were implement to the 
silica column an orange layer was able to be seen to stay in the top part of silica. 
However, there were still some challenges faced by use of flash chromatography. The 
problem was that bromotyramine derivates tended to move slowly in the silica column. 
Stronger eluents were used to receive the product out from the stationary phase but this 
probably made the impurity to stick with the product. The use of TEA in the eluents 
reduced the tailing of the products but still no pure compound was received from the 
flash chromatography. Thus, more optimization should be done in order to find the 
proper flash chromatography method. 
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The salt formation as purification method was tried after recrystallization and flash 
chromatography. It is well known that salts have higher melting point and worse 
solubility to organic solvents. Thus, it was hoped that the bromotyramine derivative salt 
form would have been solid and able to be filtered. The compound 82 was purified by 
salt formation and the product 82 HCl-salt was a white solid. After the successfull salt 
formation of 82 HCl-salt, same procedure was tried for bromotyramine derivatives 80, 
87 and 85. The compounds 80, 85 and 87 were handeled with 4 M HCl in 1,4-dioxane. 
Since the 85 HCl-salt was not able to be filtered it was handeled with oxalic acid in 
order to make oxalate salt. The 85 oxalate-salt was not soluble for the used NMR-
solvents and thus the structure or the purity were not confirmed. The filration of 87 
HCl-salt failed and the filtration of 80 HCl-salt wasn't done due to lack of time. 
However, salt formation might be a suitable method for the purification of novel 
bromotyramine derivatives if a suitable procedure is found. 
 
The composition of the novel bromotyramine derivatives at ambient room temperature 
needs to be discussed in order to understand and overcome the challenges in purification 
of these compounds. It is possible that the synthesized bromotyramines can't be 
crystallized in room temperature since their composition might be oily instead of being 
a crystal. This could be due to the freely spinning alkyls and thus insufficient 
intermolecular forces to form a solid. This is supported by the observations made couple 
times that there were a solid in the flask after recrystallization when the product was in 
a freezer. When the product was tried to be filtered in room temperature it melted and 
went through the sinter. It is possible that in lower temperatures the intermolecular 
forces of bromotyramine derivates are strong enough to from a solid.  
 
7.5 Disulfide bromotyramine 
 
The synthesis of disulfide bromotyramine 57 started from the protection of 71 (Scheme 
20). The reaction was done in large scale to have enough protected thiol 72 for the 
formation of disulfide. The mechanism of the reaction was same than seen above with 
4-methoxybenzylchloride 90, SN2 reaction where the nucleophilic free electron pair of 
sulfur attacks to the acetyl chloride (Scheme 19, p. 44). The used solvent was DCM. 
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Scheme 20. The first two successful steps of synthesis of disulfide. The reaction route 
was tested using 91 as a model compound. 
 
The reaction was succeeded and the yield of purified product 72 was 63%. Even though 
the reaction succeeded and the compound 72 was able to be purified with flash 
chromatography, the choice of protective group was not optimal. This was due to the 
similar boiling points for 3-mercaptopropionic acid 71 (111 °C), AcOH (118 °C) and 3-
(acetylthio)propanoic acid 72 (127 °C). The AcOH was not able to be evaporated in 
rotavapor since the boiling point with the product 72 was so similar. Due to similar 
properties there wasn't a great difference seen in the TLC Rf values either. However, the 
product was able to be purified with large volume manual flash chromatography. 
Hindsight, it would have been more convenient to protect the thiol with larger 
substituent that would have increased the boiling point. The next step was decided to be 
tested with 4-methoxybenzylamine 91 (Scheme 20). This would show if the designed 
route worked without using purpurealidin E 13. A different crosslinking agent CDI was 
used with DIPEA as a base and the solvent was DCM. The idea was to test different 
reagents and their function in the amidation reaction. Since the NMR-data did not show 
assumed product 92a the reaction was repeated with different solvent, THF. Again, the 
NMR-spectrum did not show assumed product 92b. Thus, it was assumed that CDI and 
DIPEA were not suitable reagents for the reaction. The reaction was made third time 
with EDC and DMAP. Again, the NMR-spectrum of 92c did not suggest that the 
reaction was completed, since the integrals of the spectrum was not logic. Now, the 
possibility of mixture of 91 starting material and the product 92 was considered. The 
compound was purified with automated flash chromatography with yield 28% and 
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NMR-spectrum showed the assumed product 92c. Since the amidation was managed to 
be done with 91, the amidation between 13 and 72 was done in similar reaction 
conditions than 92c (general procedure 1). The 
1
H-NMR identified crude product of 73 
was orange oil and the yield of the reaction was 29%. Unfortunately, there was no time 
to finish the designed reaction route of 92c or 73.  
 
7.6 Biological activity 
 
The compounds 84 and 81 activity against potassium channel (EAG) were tested as part 
of MAREX project. The activity test was made due to the request of Leuven University. 
Potassium EAG channels play important role in actio potential and neuronal 
excitability. The activity of clathrodin analogs against sodium channels was recently 
studied in master's thesis work done in University of Helsinki (Leino 2013). The 
compounds did not show any activity with the tested concentrations up 5 µM.  
 
The activity test made against HCV replicons with compounds 84, 81 and 82 HCl-salt 
showed potential antiviral activity (Figure 20) (Table 4). The salt from of purpurealidin 
E 13b HCl-salt did not show significant activity against HCV. The test was made with 
two different concentrations 25µM and 50 µM. Both of the used concentrations of 
bromotyramine derivatives 84, 81 and 82 HCl-salt showed potential activity against 
HCV replicon. Additionally, neither of the used concentrations showed HCV activity 
for 13b HCl-salt. The standard deviations were small. The cytotoxity of the compounds 
will be screened in the near future in University of Helsinki. 
 
Table 4. HCV activity with average inhibition (AVG), standard deviation (SD), 
relatively standard deviation (RSD) and standard error of the mean (SEM) 
 6-azau. 
60 µM 
13b 
HCl-
salt  
50 µM 
13b 
HCl-
salt  
25 µM 
84  
50 µM 
84  
25 µM 
82 
HCl-
salt  
50 µM 
82 
HCl-
salt   
25 µM 
81  
50 µM 
81  
25 µM 
AVG 49.03 36.52 15.47 94.04 72.87 96.16 63.51 92.64 82.37 
SD 0.15 2.81 6.59 0.97 0.33 1.56 0.93 1.67 2.49 
RSD 0.3 7.7 42.61 1.03 0.46 1.62 1.47 1.8 3.02 
SEM 0.09 1.62 3.81 0.56 0.19 0.9 0.54 0.96 1.44 
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The results are linear with biological activity tests found from literature. Purpurealidin E 
13 and similar compounds such us moloka'iamine 9 haven't showed as much biological 
activity than larger bromotyramines derivatives. The activities of the novel compounds 
84, 81 and 82 HCl-salt are almost three fold higher compared to 13b HCl-salt. This 
suggests that the carboxylic acid part is critical for the biological activity. The SAR 
could be studied more by using aromatic carboxylic acids such as 60 as positive control. 
The carboxylic acid could be methylated to ester in order to prevent the effects of free 
acid functionality. If the methylated carboxylic acid hasn't any activity against HCV by 
itself, it would provide information that purpurealidin E region is needed for HCV 
inhibition. This again would provide information from the possible SAR. 
 
 
Figure 20. Activity of the tested compounds against HCV replicons 
 
All of the three synthesized novel compounds have almost equally strong activity 
against HCV replicons at sample concentration 50 µM (Figure 20). At the used 
concentration 25µM, 81 has slightly stronger activity compared to 84 and 82 HCl-salt. 
The gap of inhibition percent between two different concentrations is smallest for 81. 
Even though the differences in inhibitions are small, it might be that large substituents 
in carboxylic acid part are favorable for BA against HCV. Synthesis of bromotyramine 
derivatives with large substituents in the carboxylic acid part could provide more 
information about this. 
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The tested compounds against HCV replicon showed potential antiviral activity. 
However, the cytotoxity needs to tested as well. For instance, Hamann and Scheuer 
(1993) noticed antiviral activity for the small aromatic aldehyde 10, but the compound 
was found out to be cytotoxic as well. The possibility that the activity against HCV is 
due to cytotoxity needs to be excluded. If the compounds aren't cytotoxic, the activity 
against HCV might be due to an unknown mechanism. This would make 
bromotyramine derivatives highly interesting compounds that would require more 
research. 
 
 
8 CONCLUSION 
 
The research of marine species as novel lead compounds have developed greatly in the 
last decades and the work has lead to first-in-class medicines approved by FDA or 
EMEA. However, due to the limitations and challenges in the marine exploring there 
are still great potential for new discoveries. Sponges and the microbes living in 
symbiosis with them have been one of the most interesting marine specie for many 
researchers.  
 
The aim of this thesis was to use purpurealidin E 13 as starting material for 
bromotyramine derivatives that would mimic 23. Purpurealidin E 13 and total amount 
of 11 bromotyramine derivatives 79-89, were successfully synthesized. Three of the 
synthesized bromotyramine derivatives, 84, 81 and 82 HCl-salt, were able to purified 
and their biological activity were evaluated with 13b HCl-salt. Purpurealidin E 13b 
HCl-salt did not have any biological activity but all the three purified compounds 84, 
81 and 82 HCl-salt showed potential activity against HCV. The cytotoxity of the 
compounds needs to be screened. If the compounds are not cytotoxic, the activity 
against HCV might be due to an unknown mechanism. 
 
In order to study the activity more, a proper purification method for novel 
bromotyramine derivatives needs to be developed. Additionally, the reaction route 
could be changed and the "three step" synthesis of bromotyramine derivatives should be 
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tested (Scheme 17, p. 42). The synthesis of disulfide bromotyramine derivate should be 
carried to the end since the 57 might have interesting biological activity.  
 
 
9 EXPERIMENTAL 
 
9.1 Reagents and devices used in thesis 
 
The reagents and solvents used in the experiments are listed below (Table 5). All the 
reagents listed were commercially available. The purity and the manufacturer are listed 
if the data was available.  
 
The NMR-spectrums were measured with Varian Mercury 300 MHz -spectrometer 
(CA, USA). The used NMR-solvents d1-chloroform (CDCl3), d4-methanol (CD3OD), 
d6-dimethyl sulfoxide (d6-DMSO) and heavy water (D2O) were all purchased from 
Cambridge Isotope Laboratories, Inc. (MA, USA). Chemical shifts (δ) are given in parts 
per million (ppm) relative to the NMR reference solvent signals (CDCl3: 7.26 ppm; 
CD3OD: 3.31 ppm; d6-DMSO: 2.50 ppm). Multiplicities are indicated by s (singlet), br s 
(broad singlet), d (doublet), dd (doublet of doublet), t (triplet), dt (doublet of triplets), q 
(quartet) and m (multiplet). The NMR-spectra from the crude products included 
impurity peaks for example from solvents that are not reported. 
 
Table 5. Reagents and solvents, their purity and supplier used in the experimental. 
Reagent or solvent Purity Supplier 
   
1,1'-Carbonyldiimidazole (CDI) ≥97% Aldrich 
1,4-Dioxane, extra dry 99.8% Acros 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide•HCl 
(EDC• HCl) 
≥98.0% Fluka or ABCR 
2-Propanol ≥99.9% Sigma-Aldrich 
7 N NH3/MeOH  Sigma-Aldrich 
3,5-Dibromobenzoic acid 98.0% Alfa Aesar 
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3,5-Dichlorobenzoic acid 97.0% Aldrich 
3,5-Difluorobenzoic acid 97.0% Sigma-Aldrich 
3,5-Dimethylbenzoic acid 99.0% Aldrich 
3-Bromobenzoic acid 98.0% Aldrich 
3-Dimethylamino-1-propyl chloride hydrochloride 96.0% Sigma-Aldrich 
3-Mercaptopropionic acid ≥99.0% Fluka 
4 M HCl in 1,4-dioxane  Sigma-Aldrich 
4-Bromo-3,5-dimethoxybenzoic acid 97.0% Aldrich 
4-Bromobenzoic acid ≥98.0% Aldrich 
4-Dimethylaminopyridin (DMAP) 99.0% Aldrich 
4-Hydroxybenzoic acid ≥98.0% Merck/ Fluka/ Sigma-
Aldrich 
4-Methoxybenzoyl chloride ≥98.0% TCI America 
4-Methoxybenzylamine 98.0% Aldrich 
5-Methylisoxazole-3-carboxylic acid ≥98.0% Alfa Aesar 
Acetic acid 100.0% Merck 
Acetic acid ≥98.0% Sigma-Aldrich 
Acetone 99.8% Sigma-Aldrich 
Acetyl chloride 98.0% Aldrich 
Ammonia (NH3) min. 25%  VWR Chemicals 
Benzoic acid  University pharmacy 
Bromine ≥99.5% Fluka 
Dichloromethane 99.8% Sigma-Aldrich 
Dichloromethane (anhydrous) ≥99.8% Sigma-Aldrich 
Diethyl ether 99.8% Sigma-Aldrich 
Di-t-butyl dicarbonate 98.0% Fluka 
Ethyl acetate ≥99.5% Sigma-Aldrich 
Hexane ≥97.0% Sigma-Aldrich 
Hydrochloric acid  ≥37% Sigma-Aldrich 
Indole-2-carboxylic acid 98% Sigma-Aldrich 
Iodomethane ≥99.0% Sigma-Aldrich 
Lithium hydroxide monohydrate ≥99.0% Sigma-Aldrich 
Methanol  ≥99.9% Sigma-Aldrich 
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Methanol anhydrous  ≥99.8% Sigma-Aldrich 
N,N-Diisopropylethylamine (DIPEA) ≥98.0% 
or 
≥99.5% 
Fluka/ Sigma-Aldrich 
N,N-dimethylformamide  99.8% Acros 
O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU) 
≥98.0% Aldrich 
Oxalic acid 98% Aldrich 
Oxalyl chloride (in a two-neck flask, supplier and purity 
unknown) 
  
p-anisoyl chloride ≥97% Fluka 
Potassium carbonate ≥99.5% Merck 
Sodium hydrogen carbonate  100.0% VWR Chemicals 
Sodium hydroxide ≥99.0% Merck 
Sodium sulfate ≥99.0% Merck 
Tetrahydrofuran ≥99.9% Sigma-Aldrich 
Tetrahydrofuran (anhydrous) ≥99.9% Sigma-Aldrich 
Thionyl chloride (in a two-neck flask, supplier and purity 
unknown) 
  
Triethylamine ≥99.5% Sigma-Aldrich 
Triethylamine (anhydrous) ≥99.5% Sigma-Aldrich 
Trifluoroacetic acid ≥99.0% TCI 
Tyramine  ≥98% Alfa Aesar 
Tyramine•HCl 99.0% Merck 
   
 
FTIR (ATR) measurements were made with Bruker Vertex 70 FT-IR (Ettlingen, 
Germany). All the spectrums were taken from the used NMR-solvents and the solvents 
were evaporated before making the measurement. Used resolution was 4, number of 
scans 64 and the measurement area was 4000-650. Wide or broad peaks are indicated 
with "(w)". The melting points were measured with MP Electrothermal Engineering 
IA9100 (Essex, Great Britain) and are uncorrected. The used rotavapor was Heidolph 
Laborota 4003 control (Schwabach, Germany). pH-paper used was made by Macherey-
nagel (Duren, Germany). 
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For the HRMS-spectrums the compounds were ran through Waters Acquity UPLC-
system (MA, USA). The mobile phase consisted of H2O (A) and acetonitrile (B) 
(Chromasolv grade, Steinheim, Germany) both containing 0.1% HCOOH (Steinheim, 
Germany). The composition of the mobile phase varied (gradient elution) in the 
following way: 0-6 min A 95% -> 5%, 1 min equibl. = total 7 min. The compounds 
were separated on a Acquity UPLC BEH C18 column (1.7 µm, 50 x 2.1 mm, Waters, 
Ireland) in 40°C. The injection volume was 2 µl and the flow-rate of the mobile phase 
was 0.6 ml/min. Tray temperature was 10 °C. The used MS-detector was Waters Synapt 
G2 HDMS (MA, USA) with the ESI (+), high resolution mode. Samples were analyzed 
in positive ion mode, with capillary voltage at 3.0 kV. The source temperature was 120 
°C desolvation temperature was set to 350 °C. Gas flow rate was from 20 L/h to 800 
L/h. The direct MS (without LC) of 13b HCl-salt was taken with PE SCIEX API 300 
mass spectrometer (Concord, Canada). 
 
Manual flash chromatography was made with silica ordered from Merck (Silica gel 60, 
0.040-0.063mm). The automated flash chromatography was made with Biotage SP1 
flash chromatography purification system with 254 nm UV-detector (Uppsala, Sweden). 
The used TLC-plates were provided by Merck (Silica gel 60-F254). CAMAG dual 
wavelenght (254/366) was used for TLC detection (Muttenz, Switzerland). Some of the 
TLC-plates were colored with ninhydrin (1.5g ninhydrin in 100 ml of ethanol), 
dinitrophenylhydrazine (12.0 g of 2,4-dinitrophenylhydrazine, 60.0 ml of conc. sulfuric 
acid and 80.0 ml of water in 200.0 ml of 95.0% ethanol) or bromocresol green (0.04 g 
of bromocresol green in 100.0 ml of absolute ethanol. 0.1 M NaOH till blue color). The 
cation exchange was made with Biotage - ISOLUTE SCX-2 (Uppsala, Sweden). 
 
9.2 Synthesis 
 
2-(3,5-Dibromo-4-hydroxyphenyl)ethan-1-aminium bromide (39a) (39b) (39c) This 
reaction was performed three times:  
 
39a: Hydrochloride salt of 1 (2.00 g, 11.5 mmol) was dissolved in 50 ml of AcOH and 
10 ml H2O. After 10 minutes, bromine (1.49 ml, 29.0 mmol, 2.5 eq) was added 
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dropwise. The solution was stirred at ambient room temperature overnight (24 hr). TLC 
did not indicate that the reaction was completed. More bromine (0.60 ml, 11.5 mmol) 
was added to the reaction till the solution was dark red. After a while, 60 ml of EtO2 was 
added to the system. The product was filtered and washed with EtO2. The filtration 
provided white powder, 3.01 g (69.2% yield).  
 
39b: Hydrochloride salt of 1 (4.00 g, 23.0 mmol) was dissolved in 100 ml of AcOH and 
20 ml H2O. After 10 minutes, bromine (4.15 ml, 81.0 mmol, 3.5 eq) was added 
dropwise. The solution was stirred at ambient room temperature overnight (24 hr). TLC 
did not indicate that the reaction was completed. After adding more bromine (2.37 ml, 
46.0 mmol, 2 eq) product was filtrated with similar way than earlier. Reaction time was 
19 hr. White powder 6.02 g. (79.0% yield). 
  
39c: Tyramine 1 (2.00 g, 15.0 mmol) was dissolved to 30 ml AcOH (Wada et al. 2011). 
Bromine (2.63 ml, 51.1 mmol, 3.5 eq) was added dropwise. TLC (9:1 
DCM:MeOH/ninhydrin colored) suggested reaction completion after 24 hr. The product 
filtrated with sinter and was washed with EtO2. The filtration provided white powder 
5.04 g (91.8% yield) 
 
1
H-NMR (300 MHz, d6-DMSO) δ 7.83 (s, 1H), 7.46 (s, 2H), 3.04 (t, J = 7.3 Hz, 2H), 
2.79 (t, J =  7.4, 2H). 
13
C-NMR (75 MHz, d6-DMSO) δ 149.43, 132.47, 131.62, 111.94, 
39.58, 39.52, 31.14.  
 
1
H-NMR (300 MHz, CD3OD) δ 7.54 (s, 2H), 3.25 (t, J = 7.5 Hz, 1H), 2.97 (t, J = 7.6 
Hz, 2H). 
13
C-NMR (75 MHz, CD3OD) δ 150.18, 132.28, 130.54, 111.13, 40.29, 31.47. 
 
t-Butyl (3,5-Dibromo-4-hydroxyphenethyl)carbamate (36a) (36b) (36c). This 
reaction was performed three times: 
 
36a: Compound 39a (2.00 g, 5.32 mmol) and Boc2O (1.39 g, 6.38 mmol, 1.2 eq) were 
dissolved to anhydrous MeOH (50 ml) under argon atmosphere. TEA (2.23 ml, 16.0 
mmol, 3 eq) was added slowly after a while. TLC (3:1Hex:EtOAc) indicated near 
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completion of reaction. Reaction time was 19.5 hr at ambient room temperature. MeOH 
was concentrated in vacuo with rotavapor. The product was extracted with EtOAc (40 
ml) and washed with 40 ml of 1 M HCl. The 1 M HCl phase was re-extracted with 20 
ml of EtOAc. Combined EtOAc (60 ml) phase was washed with water (~ 50 ml) till the 
pH was neutral. Organic phase was dried over anhydrous Na2SO4, filtrated with cotton 
wool and evaporated in vacuo with rotavapor. For more sufficient evaporation the 
product was dissolved in DCM. When DCM was evaporated in vacuo with rotavapor 
white solid appeared 2.02 g (96.3% yield).  
 
36b: Compound 39b (5.90 g, 15.7 mmol) and Boc2O (4.10 g, 18.8 mmol, 1.2 eq) were 
dissolved to anhydrous MeOH (110 ml) under argon atmosphere. TEA (6.58 ml, 47.2 
mmol, 3 eq) was added similarly. TLC (2:1 Hex:Acetone + 2% TEA) suggested 
completion of reaction after 21 hr at ambient room temperature. Reaction work-up was 
done similarly than in the previous time. Dark green solid powder appeared after 
evaporation of organic phase, 5.80 g (93.5% yield).  
 
36c: Compound 39c (5.04 g, 13.4 mmol) and Boc2O (3.51 g, 16.1 mmol, 1.2 eq) were 
dissolved to anhydrous MeOH (75 ml) under argon atmosphere. TEA (5.61 ml, 40.2 
mmol, 3 eq) was added similarly. TLC (3:1 Hex:EtOAc/ninhydrin colored) suggested 
completion of reaction after being overnight at ambient room temperature. Work-up 
similarly than earlier. The rest of the organic solvents was evaporated in oil-pump. 
White powder with orange spots. The product was purified by flash chromatography 
(8:2 Hex:EtOAc). The used amount of silica was 100 ml. Tubes containing the wanted 
product were combined and evaporated in vacuo with rotavapor. White powder, 4.36 g 
(82.5% yield). 
 
1
H-NMR (300 MHz, CDCl3) δ 7.28 (s, 2H), 5.79 (s, 1H), 4.52 (s, 1H), 3.31 (q, J = 6.8 
Hz, 2H), 2.70 (t, J = 7.0 Hz, 2H), 1.44 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 155.92, 
148.16, 133.86, 132.39, 110.19, 109.97, 41.81, 34.95, 28.55. 
1
H-NMR is in accordance 
with literature (Kotoku et al. 2005). 
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t-Butyl [3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]carbamate, (38a) 
(38b) (38c) This reaction was performed three times: 
 
38a: Compound 36a (2.00 g, 5.06 mmol), 40 (0.96 g, 6.07 mmol, 1.2 eq) and K2CO3 
(1.75 g, 12.3 mmol, 2.5 eq) were dissolved in anhydrous acetone (50 ml) under argon 
atmosphere and heated to reflux (77 °C) overnight (19 hr). TLC (3:1 Hex:EtoAc) 
indicated near completion of reaction. The solution was filtered with Büchner funnel in 
vacuo. The filtered organic phase was concentrated in vacuo with rotavapor. The 
remained acetone was extracted with 45 ml DCM and washed with 30 ml 0.1 M NaOH 
and with water (3x30 ml). Organic phase was dried over anhydrous Na2SO4, filtrated 
with cotton wool and evaporated in vacuo with rotavapor. Due to the impurities seen in 
TLC (9:1 DCM:MeOH) the product was recrystallized. It was dissolved in 15 ml 
hexane and heated till the boiling point to reflux. During the recrystallization brown 
solid was formed. The solution was transferred to new flask without the brown solid. 
The solution was cooled down slowly first at room temperature then in ice-bath. The 
appeared white solid was filtered with in vacuo, 1.59 g (65.3% yield). 
 
38b: Compound 36b (5.66 g, 14.3 mmol), 40 (2.72 g, 17.2 mmol, 1.2 eq) and K2CO3 
(4.95 g, 35.8 mmol, 2.5 eq) was dissolved in anhydrous acetone (80 ml) under argon 
atmosphere and heated to reflux (77 °C). TLC (2:1 Hex:Acetone + 2% TEA) 5 hr later 
did not suggest completion of reaction so it was leaved overnight. After 23 hr reaction 
work-up similarly than earlier. The rest of the solvent was dissolved with oil-pump, 
dark brown powder appeared. Recrystallization similarly than earlier. White powder 
4.49 g (65.3% yield). 
 
38c: Compound 36c (4.36 g, 11.0 mmol), 40 (2.10 g, 13.3 mmol, 1.2 eq) and K2CO3 
(3.81 g, 27.6 mmol, 2.5 eq) were dissolved in anhydrous acetone (95 ml) under argon 
atmosphere and heated (77 °C) to reflux. TLC (3:1 Hex:EtOAc/ninhydrin colored) 
suggested near completion of reaction after 19 hr. Work-up similarly than earlier. White 
powder, 3.91 g (74.0% yield). 
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1
H-NMR (300 MHz, CDCl3) δ 7.32 (s, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.32 (q, J = 6.8 
Hz, 2H), 2.71 (t, J = 7.0 Hz, 2H), 2.58 – 2.49 (m, 2H), 2.27 (s, 6H), 2.09 – 1.98 (m, 
2H), 1.44 (s, 9H). 
1
H-NMR is in accordance with literature (Kottakota et al. 2012). 
 
3-[4-(2-Aminoethyl)-2,6-dibromophenoxy]-N,N-dimethylpropan-1-amine, 
purpurealidin E (13a) (13b) (13c) This reaction was performed three times: 
 
13a: Compound 38a (1.59 g, 3.30 mmol) was dissolved in 35 ml anhydrous DCM under 
argon atmosphere. By miscalculation, too much TFA (17.8 ml, 232.5 mmol, 70.4 eq) 
was added slowly, when the amount should have been (1.50 ml, 19.5 mmol, 6.0 eq). 
TLC (9:1 DCM:MeOH) indicated the completion of reaction after 3 hr. The solution 
was concentrated in vacuo with rotavapor. The product was extracted with 15 ml EtOAc 
and washed with 15 ml 2 M NaOH. To the used NaOH was added more NaOH till the 
pH~7 and it was re-extracted with 15 ml EtOAc. Finally, combined EtOAc phase was 
washed with water. Organic phase was dried over anhydrous Na2SO4, filtrated with 
cotton wool and evaporated in vacuo with rotavapor. The water phase was re-extracted 
again with total amount 75 ml of EtOAc and 15 ml of 5 M NaOH in three steps. TLC 
(9:1 DCM:MeOH) indicated that at this time the extraction was fine. Organic phase was 
dried over anhydrous Na2SO4, filtrated with cotton wool and evaporated in vacuo with 
rotavapor. The product was kept in oil-pump till there was no EtOAc left. Orange, oily 
gum 1.01 g (80.4% yield). Small amount of the product (50 mg) was purified by using 
flash chromatography (9:1 DCM:MeOH) for the HRMS.  
 
FT-IR: 3393 (w), 2956, 1691, 1460, 1265, 1051, 739 HRMS (ESI+): Calculated value 
379.0021 (C13H21N2OBr2), found value 379.0024 and pseudomolecular ion peak 
379.0003.  
 
13b: Compound 38b (4.49 g, 9.35 mmol) was dissolved in 40 ml anhydrous DCM 
under argon atmosphere. TFA (4.30 ml, 56.0 mmol, 6 eq) was added slowly. TLC (2:1 
Hex:Acetone + 2% TEA) 2 hr later did not suggest completion of reaction so it was 
leaved overnight. After 18 hr DCM was concentrated in rotavapor. The product was 
extracted with 20 ml EtOAc and washed with 20 ml 2M NaOH. NaOH was re-extracted 
59 
 
 
with total 40 ml EtOAc and washed with 2 M NaOH till the pH≥10. Organic phase was 
dried over anhydrous Na2SO4, filtrated with cotton wool and evaporated in vacuo with 
rotavapor. TLC (2:1 Hex:Acetone + 2% TEA) suggested that the reaction didn't work as 
wanted. The product was dissolved again in 25 ml anhydrous DCM under argon 
atmosphere. TFA (7.2 ml, 96.8 mmol, 40 eq) was added slowly. TLC (2:1 Hex:Acetone 
+ 2% TEA) suggested now that the reaction was completed after 19.5 hr at ambient 
room temperature. Work-up similarly than earlier. The product was kept in oil-pump till 
there was no solvent left. Orange, oily gum 2.22 g (62.5% yield). 
 
1
H-NMR (300 MHz, CDCl3) δ 7.34 (s, 2H), 4.04 (t, J = 6.4 Hz, 2H), 2.94 (t, J = 6.8 Hz, 
2H), 2.65 (t, J = 7.0 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 2.31 (s, 6H), 2.06 (m, 2H), 1.55 
(br s, 2H). FT-IR: 2955, 2820, 2772, 1547, 1460 , 1265, 1051, 741. HRMS (ESI+): 
Calculated value 379.0021 (C13H21N2O Br2), found value 379.0022. There was other 
peaks with different mass value found as well. 
 
Small amount of 13b (50 mg) was dissolved to MeOH and it was inserted to ISOLUTE 
SCX-2 cation exchange column. The sorbent was first washed with MeOH and then 
with 3.5 N NH3/MeOH solution. The combined solution from tubes was evaporated 
with rotavapor. Orange, oily gum 50 mg (100% yield). No significant changes in the 
NMR nor in the FTIR was noticed. 
 
13c: Compound 38c (3.00 g, 6.25 mmol) was dissolved in 30 ml anhydrous DCM under 
argon atmosphere. TFA (19.1 ml, 250.0 mmol, 40 eq) was added slowly. TLC (9:1 
DCM:MeOH/ninhydrin colored) suggested that the reaction was completed after 19 hr 
at ambient room temperature. DCM was washed multiple times with 2 M NaOH till pH 
>7. Re-extraction from water phase was done with DCM. Organic phase was dried over 
anhydrous Na2SO4, filtrated with cotton wool and evaporated in vacuo with rotavapor. 
The remained solvent was evaporated with oil-pump. Orange, oily gum 1.25 g (52.5% 
yield). 
 
1
H-NMR (300 MHz, CDCl3) δ 7.32 (s, 2H), 4.03 (t, J = 6.4 Hz, 2H), 2.93 (t, J = 6.9 Hz, 
2H), 2.64 (t, J = 6.8 Hz, 2H), 2.61 – 2.54 (m, 2H), 2.29 (s, 6H), 2.10 – 1.97 (m, 2H). 
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13
C-NMR (75 MHz, CDCl3) δ 151.75, 138.68, 133.00, 118.28, 110.15 (Peak from 
TFA), 71.98, 56.49, 45.52, 43.27, 38.89, 28.30. 
 
2-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenyl]ethan-1-aminium chloride 
(13b HCl-salt):  
 
The product treated with cation exchange sorbent 13b (50 mg) was dissolved in 2 ml of 
1,4-dioxane. Excessive amount of 4 M HCl in 1,4-dioxane was added (0.80 ml). The 
appeared orange solid was filtered and washed with EtO2, 29.3 mg (53.5% yield). 
 
1
H-NMR (300 MHz, CD3OD) δ 7.58 (s, 2H), 4.14 (t, J = 5.6 Hz, 2H), 3.56 – 3.49 (m, 
2H), 3.22 – 3.13 (m, 2H), 2.97 (s, 6H), 2.96 – 2.89 (m, 2H), 2.36 – 2.25 (m, 2H). 13C-
NMR (75 MHz, cd3od) δ 153.02, 137.73, 134.46, 119.31, 71.14, 57.00, 43.70, 41.40, 
33.11, 26.41. FT-IR: 3370 (w), 2940 (w), 2480 (w), 1464, 1267, 1051, 736. Rf = 0,44 
(1:1 DCM:MeOH + TEA 1%). HRMS (ESI+): Calculated value 379.0021 (C13H21N2O 
Br2), found value 379.0025. There were other peaks with different mass value found as 
well e.g. m/z: 379.0 
 
3,5-Dibromo-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-4-
hydroxybenzamide (77) 
 
Carboxylic acid 62 (93.0 mg, 0.316 mmol, 1.2 eq), EDC•HCl (60.5 mg, 0.316 mmol, 1.2 
eq), DIPEA (0.055 ml, 0.316 mmol, 1.2 eq) and 13a (100 mg, 0.263 mmol, 1.0 eq) were 
dissolved in DMF under argon atmosphere. After 25 hr at ambient room temperature 
TLC (4:1 DCM:MeOH) indicated completion of reaction. DMF was concentrated in 
rotavapor. The product was extracted with EtOAc and washed with water and sat. 
NaHCO3. While washing the organic phase, pH was adjusted with 2 M H2SO4. No 
product was managed to get out from the extraction.  
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N-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-3,5-difluorobenzamide 
(78) 
 
Carboxylic acid 64 (50.0 mg, 0.316 mmol, 1.2 eq), EDC•HCl (60.5 mg, 0.316 mmol, 1.2 
eq), DIPEA (0.055 ml, 0.316 mmol, 1.2 eq) and 13a (100 mg, 0.263 mmol, 1.0 eq) were 
dissolved in DMF under argon atmosphere. After 24 hr TLC (9:1 
DCM:MeOH/ninhydrin colored) indicated completion of reaction. DMF was 
concentrated in rotavapor. The product was dissolved in EtOAc and washed with NH3 
and water. Organic phase was dried over anhydrous Na2SO4, filtrated with cotton wool 
and evaporated in vacuo with rotavapor. The product was yellow gum and yield of the 
crude product was 100 mg (73.0%). 
1
H-NMR-spectrum indicated multiple impurities 
and the peaks of the possible product were not recognized. The product was purified 
with Biotage flash chromatography (weak solvent 9:1 DCM:MeOH, strong solvent: 
MeOH). The eluents collected to the tubes were combined to two sections and the 
eluents were  evaporated with rotavapor. The yield of first section was 37.3 mg (27.2%) 
and the yield of the second section was 28.3 mg (20.7%). 
1
H-NMR did not show any 
expected product in either of the sections.  
 
General procedure 1: Synthesis of amides from 13 and carboxylic acids 
 
Carboxylic acid (1.1 or 1.2 eq), EDC•HCl (60.5 mg, 0.316 mmol, 1.2 eq) and DMAP 
(38.6 mg, 0.342 mmol, 1.3 eq) were added in anhydrous DCM (5-10 ml) under argon 
atmosphere. While the solids were dissolving, 13a-c (100 mg, 0.263 mmol, 1.0 eq) was 
dissolved in 1-2 ml anhydrous DCM in separate flask under argon atmosphere. After 15 
minutes, dissolved 13 was added to the reaction. The reaction was kept at ambient room 
temperature and it was followed by TLC. The reaction times varied. After the 
completion of reaction, 15 ml of DCM was added to dilute the concentration. Organic 
phase was washed with the following method: 1. 20 ml Brine/H2O 1:1, 2. 20 ml 
brine/NH3 25% 1:1, 3. 20 ml brine/HCl 1 M 1:1, 4. 20 ml brine/NH3 25%, 5. 2x20 ml 
brine. Organic phase was dried over anhydrous Na2SO4, filtrated with cotton wool and 
evaporated in vacuo with rotavapor. The remained products were dried with in an oil-
pump.   
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3,5-Dibromo-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]benzamide 
(80) 
 
Carboxylic acid 59 (81.0 mg, 0.289 mmol, 1.1 eq) and other reagents were added as in 
procedure 1. Reaction was left over the weekend since the TLC (2:1 Hex:Acetone + 2% 
TEA) indicated incomplete reaction. Extra 0,3 eq of DMAP was added since the TLC 
did not indicate completed reaction. Reaction time was 95 hr. Unlike in procedure 1, the 
product was washed with EtOAc. The product was purified by recrystallization by using 
hexane and drops of methanol. White powder, 38.2 mg (22.6% yield).  
 
1
H-NMR (300 MHz, CDCl3) δ 7.79 (t, J = 1.7 Hz, 1H), 7.76 (d, J = 1.7 Hz, 2H), 7.37 
(s, 2H), 4.07 (t, J = 6.4 Hz, 2H), 3.64 (q, J = 6.8 Hz, 2H), 2.85 (t, J = 7.0 Hz, 2H), 2.63 
(t, J = 6.6 Hz, 2H), 2.33 (s, 6H), 2.09 (m, J = 6.7 Hz, 2H). 
13
C-NMR (75 MHz, CDCl3) 
δ 137.91, 137.32, 137.13, 133.07, 129.03, 123.55, 118.66, 110.19, 72.01, 56.48, 45.45, 
41.31, 34.52, 28.19, 26.41. Mp. 100-102 °C. Rf = 0.44 (1:1 DCM:MeOH + TEA 1%). 
HRMS (ESI+): Calculated value 638.8493 (C20H23N2O2Br4), found value 638.8487. 
 
Due to impurity peak seen in MS-spectrum and H-NMR, flash chromatography was 
made for a small amount (6.3 mg) of the product. Used eluent was 3:1 DCM:MeOH. 
Combined solvents from tubes were evaporated in rotavapor. The yield was 5.2 mg of 
product 80 (82.5%). No improvements in purity were seen in 
1
H-NMR.  
 
N-[3-[2,6-Dibromo-4-[2-(3,5-dibromobenzamido)ethyl]phenoxy]propyl]-N-
methylmethyliumaminium chloride (80 HCl-salt) 
 
The whole amount of the 80 was dissolved in 1,4-dioxane. Excessive amount of 4 M 
HCl in 1,4-dioxane was added (0.50 ml). Extra dioxane was evaporated with running 
airflow. White powder appeared to dioxane but there was not enough time to try filter it. 
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3,5-Dichloro-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]benzamide 
(84) 
 
Carboxylic acid 65 (55.0 mg, 0.289 mmol, 1.1 eq) and other reagents were added as in 
procedure 1 with the exception that the used amount of DMAP was 1,5 eq. Reaction 
was completed according to TLC (2:1 Hex:Acetone + 2% TEA) after 20 hr. The product 
was purified by recrystallization by using hexane and DCM as solvents. Filtration gave 
white solid 19.0 mg (13.0%),  
 
1
H-NMR (300 MHz, CDCl3) δ 7.57 (d, J = 1.9 Hz, 2H), 7.49 (t, J = 1.9 Hz, 1H), 7.37 
(s, 2H), 6.09 (s, 1H), 4.06 (t, J = 6.4 Hz, 2H), 3.65 (q, J = 6.7 Hz, 2H), 2.85 (t, J = 7.0 
Hz, 2H), 2.63 (t, J = 7.7 Hz, 2H), 2.33 (s, 6H), 2.09 (m, 2H). 
13
C-NMR (75 MHz, 
CDCl3) δ 165.22, 152.28, 137.48, 137.32, 135.77, 133.06, 131.64, 125.70, 118.65, 
72.00, 56.48, 45.45, 41.30, 34.52, 28.19. FT-IR: 3305 (w), 2941, 2866, 2829, 2781, 
1647, 1562, 1546, 1452, 1250, 1050, 808, 744. Rf = 0.42 (1:1 DCM:MeOH + TEA 1%). 
HRMS (ESI+): Calculated value 550.9503 (C20H23N2O2Cl2Br2), found value 550.9503. 
 
3-[2,6-Dibromo-4-[2-(3-bromo-4-methoxybenzamido)ethyl]phenoxy]-N,N-
dimethylpropan-1-aminium chloride (82) 
 
Carboxylic acid 61 (66.9 mg, 0.289 mmol, 1.1 eq) and other reagents were added as in 
procedure 1 with the exception that the used amount of DMAP was 1,5 eq. Reaction 
was not completed according to TLC (2:1 Hex:Acetone + 2% TEA) after 44 hr, extra 61 
(0.2 eq) was added. After 2 hr TLC (2:1 Hex:Acetone + 2% TEA) suggested completion 
of reaction. Reaction time was 46 hr. 
1
H-NMR was taken from the crude product. The 
product was purified by recrystallization by using hexane and DCM. When the cold 
product was tried to be filtrated, it melted and went through the sinter. The solvent was 
evaporated in rotavapor in order to make salt from the product. 
 
1
H-NMR (300 MHz, CDCl3) δ 7.91 (d, J = 2.2 Hz, 1H), 7.67 (dd, J = 8.6, 2.2 Hz, 1H), 
7.37 (s, 2H), 6.91 (d, J = 8.6 Hz, 1H), 6.07 (s, 1H), 4.06 (t, J = 6.5 Hz, 2H), 3.94 (s, 
64 
 
 
3H), 3.64 (q, J = 7.0 Hz, 2H), 2.84 (t, J = 7.0 Hz, 2H), 2.57 (t, J = 7.4 Hz, 2H), 2.29 (s, 
6H), 2.14 – 1.98 (m, 2H). 
 
3-[2,6-Dibromo-4-[2-(3-bromo-4-methoxybenzamido)ethyl]phenoxy]-N,N-
dimethylpropan-1-aminium chloride (82 HCl-salt) 
 
The product 82 was dissolved in 10 ml 1,4-dioxane. Excessive amount of 4 M HCl in 
1,4-dioxane was added (0.50 ml). Extra dioxane was evaporated with running airflow. 
White solid appeared to dioxane. The salt was filtrated and washed with Et2O. White 
powder 44.8 mg (24.7% yield).  
 
1
H-NMR (300 MHz, CD3OD) δ 7.97 (t, J = 2.2 Hz, 1H), 7.77 (dd, J = 2.2, 8.6 Hz, 1H), 
7.51 (s, 2H), 7.09 (d, J = 8.7 Hz, 1H), 4.12 (t, J = 5.6 Hz, 2H), 3.94 (s, 3H), 3.58 – 3.47 
(m, 4H, assumed to be two triplets with two -CH2-), 2.97 (s, 6H), 2.86 (t, J = 7.1 Hz, 
2H), 2.34 – 2.23 (m, 2H). 13C-NMR (75 MHz, CD3OD) δ 168.47, 160.03, 152.16, 
140.58, 134.51, 133.39, 129.28, 128.99, 118.74, 112.70, 112.40, 71.16, 57.17, 56.97, 
43.73, 41.97, 35.22, 26.37. FT-IR: 3390 (w), 2940 (w), 2490 (w), 2370, 1640, 1535, 
1460, 1271, 1058, 756. Rf = 0.66 (1:1 DCM:MeOH + TEA 1%). HRMS (ESI+): 
Calculated value 590.9494 (C21H26N2O3Br3), found value 590.9496. 
 
3,5-Dibromo-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-4-
methoxybenzamide (81) 
 
Carboxylic acid 60b (97.9 mg, 0.316 mmol, 1.2 eq) ) and other reagents were added as 
in procedure 1. After 42 hr TLC (2:1 Hex:Acetone + 2% TEA) suggested completion of 
reaction. The product was recrystallized with hexane and few drops of methanol. White 
powder, 54 mg (31.0% yield). 
 
1
H-NMR (300 MHz, CDCl3) δ 7.86 (s, 2H), 7.36 (s, 2H), 6.11 (s, 1H), 4.06 (t, J = 6.4 
Hz, 2H), 3.92 (s, 3H), 3.63 (q, J = 6.7 Hz, 2H), 2.84 (t, J = 7.0 Hz, 2H), 2.58 (t, J = 7.4 
Hz, 2H), 2.30 (s, 6H), 2.06 (m, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 164.71, 157.07, 
152.32, 137.35, 133.05, 132.79, 131.62, 118.71, 118.65, 72.13, 60.92, 56.50, 45.56, 
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41.30, 34.55, 28.33. FT-IR: 3288 (w), 3084, 2956, 2879, 2831, 2791, 1651, 1547, 1474, 
1317, 1267, 742. Mp.: 83-85 °C. Rf = 0.59 (1:1 DCM:MeOH + TEA 1%). HRMS 
(ESI+): Calculated value 668.8599 (C21H25N2O3Br4), found value 668.8609.  
 
3-Bromo-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]benzamide (79) 
 
Carboxylic acid 58 (63.5 mg, 0.316 mmol, 1.2 eq) and other reagents were added as in 
procedure 1 with the exception that the used crosslinking agent was HBTU (41.9 mg, 
0.342 mmol, 1.3 eq). After 42 hr TLC (2:1 Hex:Acetone + 2% TEA) suggested 
completion of reaction. Recrystallization was made bu using multiple different solvents 
(hexane, 2-propanol, MeOH, acetone) but no solid appeared that could have been 
filtered. 
1
H-NMR was taken before recrystallization from the crude product, orange 
gum 111.6 mg. 
 
1
H-NMR (300 MHz, CDCl3) δ 7.86 (t, J = 1.8 Hz, 1H), 7.63 (t, J = 1.9 Hz, 1H), 7.61 (t, 
J = 1.9 Hz, 1H), 7.37 (s, 2H), 7.30 (t, J = 7.8 Hz, 1H), 4.05 (t, J = 6.4 Hz, 2H), 3.65 (q, 
J = 6.8 Hz, 2H), 2.89 – 2.82 (m, 2H), 2.61 – 2.52 (m, 2H), 2.29 (s, 6H), 2.06 (dt, J = 
6.5, 13.5 Hz, 2H). 
 
N-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-5-methylisoxazole-3-
carboxamide (88)  
 
Carboxylic acid 69 (40.1 mg, 0.316 mmol, 1.2 eq) and other reagents were added as in 
procedure 1. After 42 hr TLC (2:1 Hex:Acetone + 2% TEA) suggested completion of 
reaction. Recrystallization was done with hexane and drops of MeOH. No solid 
appeared that could have been filtered when cooled down. 
1
H-NMR was taken before 
recrystallization from the crude product, orange gum with small white spots 71.6 mg. 
 
1
H-NMR (300 MHz, CDCl3) δ 7.36 (s, 2H), 6.43 (d, J = 1.0 Hz, 1H), 4.05 (t, J = 6.4 
Hz, 2H), 3.69 – 3.58 (m, 2H), 2.83 (t, J = 7.2 Hz, 2H), 2.58 (t, J = 7.4 Hz, 2H), 2.47 (d, 
J = 0.9 Hz, 3H), 2.30 (s, 6H), 2.06 (dt, J = 6.5, 13.3 Hz, 2H). 
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N-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]benzamide (87) 
 
Benzoic acid 68 (38.6 mg, 0.316 mmol, 1.2 eq) and other reagents were added as in 
procedure 1. After 68 hr TLC (3:1 DCM:MeOH) suggested completion of reaction. The 
crude product (71.1 mg) was purified with flash chromatography (3:1 DCM:MeOH). 
The evaporated solvent from the combined tubes provided orange gum. The yield from 
the flash chromatography was 63 mg (49.6%). Recrystallization with hexane and 2-
propanol did not provide white crystals when cooled down. The 
1
H-NMR was not taken 
after the flash chromatography, since it was assumed that the pure product was solid. 
Thus, the 
1
H-NMR is from crude product before the flash chromatography.  
 
1
H-NMR (300 MHz, CDCl3) δ 7.74 – 7.69 (m, 2H), 7.46 – 7.42 (m, 2H), 7.40 (t, J = 1.6 
Hz, 1H), 7.38 (s, 2H), 4.06 (t, J = 6.4 Hz, 2H), 3.73 – 3.62 (m, 2H), 2.86 (t, J = 7.0 Hz, 
2H), 2.59 (t, J = 7.4 Hz, 2H), 2.31 (s, 6H), 2.13 – 2.00 (m, 2H). 
 
N-[3-[4-(2-benzamidoethyl)-2,6-dibromophenoxy]propyl]-N-methylmethylium-
aminium chloride (87 HCl-salt) 
 
The solvents were evaporated and the product 87 was dissolved to 4 ml 1,4-dioxane. 
Excessive amount of 4 M HCl in 1,4-dioxane was added and white solid appeared to 
solvent. The solid was tried to be filtered without success.  
 
N-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-3,5-dimethylbenzamide 
(86) 
 
Carboxylic acid 67 (47.4 mg, 0.316 mmol, 1.2 eq) and other reagents were added as in 
procedure 1. After three days TLC (3:1 DCM:MeOH) suggested completion of reaction. 
The crude product 86 (87.1 mg) was purified with the same way and the same result 
than 87. The yield from the flash chromatography was 44.9 mg and the product was 
clear gum. The 
1
H-NMR was taken from the crude product before the flash 
chromatography since it was assumed that the pure product needed to be solid.  
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1
H-NMR (300 MHz, CDCl3) δ 7.38 (s, 2H), 7.30 (s, 2H), 7.14 – 7.10 (m, 1H), 4.05 (t, J 
= 6.5 Hz, 2H), 3.68 – 3.60 (m, 2H), 2.84 (t, J = 6.9 Hz, 2H), 2.64 – 2.48 (m, 2H), 2.35 
(s, 6H), 2.29 (s, 6H), 2.06 (dt, J = 6.5, 13.2 Hz, 2H). 
 
4-Bromo-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-3,5-
dimethoxybenzamide (85) 
 
Carbocylix acid 66 (63.5 mg, 0.316 mmol, 1.2 eq) and other reagents were added as in 
procedure 1. After 47 hr TLC (3:1 DCM:MeOH/ninhydrin colored) suggested 
completion of reaction. Orange gum 136.7 mg, the 
1
H-NMR is from the crude product.  
 
1
H-NMR (300 MHz, CDCl3) δ 7.38 (s, 2H), 6.90 (s, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.93 
(s, 6H), 3.65 (q, J = 6.7 Hz, 2H), 2.87 (t, J = 6.9 Hz, 2H), 2.59 – 2.51 (m, 2H), 2.28 (s, 
6H), 2.05 (dt, J = 6.6, 13.9 Hz, 2H). 
 
N-[3-[2,6-Dibromo-4-[2-(4-bromo-3,5-dimethoxybenzamido)ethyl]phenoxy]-
propyl]-N-methylmethyliumaminium) chloride (85 HCl-salt) 
 
The product 85 was dissolved to small amount of 1,4-dioxane (1.5 ml) and 0.5 ml 4 M 
HCl in 1,4-dioxane was added. The solvent turned cloudy. No solid was appeared after 
cooled down. The 1,4-dioxane was evaporated. 
 
N-[3-[2,6-Dibromo-4-[2-(4-bromo-3,5-dimethoxybenzamido)ethyl]phenoxy]-
propyl]-N-methylmethyliumaminium] carboxyformate (85 oxalate-salt) 
 
The product 85 HCl-salt was dissolved in 2-propanol and assumed equivalent amount 
of oxalic acid (19.8 mg) was added. The solvent turned cloudy and it was kept in freezer 
overnight. The formed solid was filtered and washed with Et2O. Brown solid 10.1 mg. 
The product did not dissolve in CD3OD nor in D2O, so no NMR spectra were able to 
run. 
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N-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-1H-indole-2-
carboxamide (89) 
 
Carboxylic acid 70 (38.6 mg, 0.316 mmol, 1.2 eq) and other reagents were added as in 
procedure 1. The reaction was left over weekend. TLC (9:1 DCM:MeOH) suggested 
completion of reaction after 91 hr. Yellow solid appeared 36.6 mg. The product should 
have been purified, but the time ran out. The 
1
H-NMR is from the crude product. 
 
1
H-NMR (300 MHz, CDCl3) δ 9.42 (s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.44 (dq, J = 1.0, 
8.4 Hz, 1H), 7.39 (s, 2H), 7.36 – 7.26 (m, 1H), 7.14 (ddd, J = 1.0, 7.0, 8.0 Hz, 1H), 6.78 
(dd, J = 0.9, 2.0 Hz, 1H), 6.27 (t, J = 6.1 Hz, 1H), 4.06 (t, J = 6.5 Hz, 2H), 3.70 (q, J = 
6.8 Hz, 2H), 2.87 (t, J = 7.1 Hz, 2H), 2.56 (dd, J = 6.5, 8.3 Hz, 2H), 2.28 (s, 6H), 2.05 
(dt, J = 6.6, 13.5 Hz, 2H). 
 
S-[3-[(4-methoxybenzyl)amino]-3-oxopropyl]ethanethioate (92a), (92b), (92c)  
This reaction was made three times: 
 
92a: Thiol acid 72 (0.30 g, 2.02 mmol 1.0 eq) and CDI (0.43 g, 2.63 mmol, 1.3 eq) were 
dissolved in DCM under argon atmosphere and DIPEA (0.46 ml, 2.63 mmol, 1.3 eq) 
were added. After 25 min, 91 (0.34 ml, 2.64 mmol, 1.3 eq) was added. The reaction was 
left over weekend. After 72 hr, TLC (8:2 Hex:EtOAc) indicated completion of reaction. 
The reaction work-up as in procedure 1. The organic phase was filtered, since there was 
white crystals. The yield was 191 mg, but the 
1
H-NMR did not show assumed product.  
 
92b: The reaction was repeated with the exception that the used solvents was THF. 
After 26 hr 25 ml of EtOAc was added. The organic phase was washed with 1 M 
KHSO4, sat. NaHCO3 and water. The solvent was evaporated with rotavapor. The 
product was dissolved in EtOAc rewashed with 1 M HCl and sat NaHCO3. The solid in 
organic phase was filtered away, the organic phase was evaporated with rotavapor and 
dried in oil-pump. White solid 342.3 mg. 
1
H-NMR did not indicate the assumed 
product.  
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1
H-NMR (300 MHz, d6-DMSO) δ 7.17 (d, J = 8.6 Hz, 4H), 6.96 – 6.81 (m, 4H), 4.17 
(dd, J = 5.9, 12.8 Hz, 4H), 3.73 (s, 6H), 3.02 (t, J = 7.0 Hz, 2H), 2.42 (t, J = 7.0 Hz, 
2H), 2.31 (s, 3H). 
 
92c: Carboxylic acid 72 (0.30 g, 2.02 mmol 1.0 eq), EDC•HCl and DMAP were added 
as in procedure 1. The used solvent was anhydrous THF. After 15 min, 91 (0.34 ml, 
2.64 mmol, 1.3 eq) was added. The reaction was left over weekend. After 92 hr TLC 
(9:1 DCM:MeOH) indicated completion of reaction. THF was concentrated in 
rotavapor. The product was extracted with EtOAc and washed with 1 M HCl, sat. 
NaHCO3 and brine. The product was purified with Biotage chromatography (1:1 
Hex:EtOAc). The solvent from the combined tubes was evaporated in rotavapor and oil-
pump. White solid 153.60 mg (28.4% yield). 
 
1
H-NMR (300 MHz, d6-DMSO) δ 7.23 – 7.10 (m, 2H), 6.97 – 6.79 (m, 2H), 4.19 (d, J 
= 6.0 Hz, 2H), 3.73 (s, 3H), 3.02 (t, J = 7.0 Hz, 2H), 2.42 (t, J = 7.0 Hz, 2H), 2.31 (s, 
3H). 
13
C-NMR (75 MHz, d6-DMSO) δ 195.23, 169.76, 158.16, 131.26, 128.49, 113.62, 
55.01, 41.51, 34.84, 30.44, 24.49.  
 
S-[3-[[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]amino]-3-oxopropyl] 
ethanethioate (73) 
 
Carboxylic acid 72 (234.0 mg, 1.58 mmol, 1.2 eq) and other reagents were added like in 
procedure 1. The reaction was left over weekend. TLC (9:1 DCM:MeOH) suggested 
near completion of reaction after 92 hr. Orange oil, 194.7 mg (28.9% yield). 
 
1
H-NMR (300 MHz, CDCl3) δ 7.33 (s, 2H), 4.04 (t, J = 6.4 Hz, 2H), 3.46 (q, J = 6.9 
Hz, 2H), 3.12 (t, J = 6.9 Hz, 2H), 2.85 (t, J = 6.9 Hz, 2H), 2.74 (t, J = 7.0 Hz, 2H), 2.63 
– 2.53 (m, 2H), 2.45 (t, J = 6.9 Hz, 2H), 2.33 (s, 3H), 2.30 (s, 6H), 2.07 (dd, J = 6.5, 
14.3 Hz, 2H). 
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N-[3,5-Dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-4-methoxybenzamide 
(83) 
 
Acyl chloride 90 (50.0 mg, 0.289 mmol, 1.1 eq) and 13 (100.0 mg, 0.263 mmol, 1.0 eq) 
were dissolved in anhydrous THF in argon atmosphere. TEA (0.055 ml, 0.395 mmol, 
1.5 eq) was added. The reaction was left over weekend. The reaction time was 66 hr. 
The solvent was concentrated in rotavapor, extracted with EtOAc and washed with 25% 
NH3 and water till the pH was ~7. The water phase was re-extracted with EtOAc. 
Organic phase was dried over anhydrous Na2SO4, filtrated with cotton wool and 
evaporated in vacuo with rotavapor. The product was purified with Biotage 
chromatography (Weak solvent: 2:1 Hex:Acetone + 2% TEA, Strong solvent: DCM + 
2% TEA). The solvent of combined tubes was evaporated in rotavapor and finally in 
oil-pump, orange gum 10.4 mg (5.9% yield).  
 
1
H-NMR (300 MHz, CDCl3) δ 7.67 (dd, J = 4.7, 8.9 Hz, 2H), 7.37 (s, 2H), 6.91 (dd, J = 
4.7, 8.9 Hz, 2H), 6.08 (s, 1H), 4.05 (t, J = 6.5 Hz, 2H), 3.84 (s, 3H), 3.64 (q, J = 6.8 Hz, 
2H), 2.84 (t, J = 7.0 Hz, 2H), 2.55 (t, J = 7.2 Hz, 2H), 2.28 (s, 6H), 2.04 (m, J = 7.4, 
13.9 Hz, 2H).
 13
C-NMR (75 MHz, CDCl3) δ 167.24, 162.42, 152.16, 137.79, 133.07, 
128.77, 126.85, 118.53, 113.99, 72.15, 56.54, 55.56, 45.62, 41.03, 34.78, 28.42. HRMS 
(ESI+): Calculated value 513.0388 (C21H27N2O3Br2), found value 513.0390.  
 
3,5-Dibromo-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-4-
methoxybenzamide (81) 
 
Carboxylic acid 60a (98.0 mg, 0.316 mmol, 1.2 eq) was dissolved in anhydrous THF in 
argon atmosphere. Oxalyl chloride (0.034 ml, 0.395 mmol, 1.5 eq) and five drops of 
DMF were added. After 50 min 13a (100 mg, 0.261 mmol, 1.0 eq) was dissolved in 
anhydrous THF in argon atmosphere and TEA (0.058 ml, 0.421 mmol, 1.6 eq) was 
added. The reaction was left over weekend. After 66 hr the solvents were evaporated 
with rotavapor, extracted with EtOAc and washed with 25% NH3 and water/brine. 
Organic phase was dried over anhydrous Na2SO4, filtrated with cotton wool and 
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evaporated in vacuo with rotavapor and oil-pump. According to 
1
H-NMR there was no 
desired product.  
 
The reaction was repeated with the difference that the used acid was thionyl chloride 
(0.029ml, 0.395 mmol, 1.5 eq) instead of oxalyl chloride and the solvent was anhydrous 
DCM. Before adding the amine, the formation of acyl chloride was followed with TLC 
(9:1 DCM:MeOH + 1% TEA). After 11 hr it suggested near completion of the acyl 
chloride formation and 13a (100 mg, 0.261 mmol, 1.0 eq) was dissolved in anhydrous 
DCM and TEA (0.058 ml, 0.421 mmol, 1.6 eq) was added. TLC suggested near 
completion of the reaction after 24 hr. The solvents was evaporated with rotavapor, 
extracted with EtOAc, washed with 25% NH3 and water/brine and the water phase was 
re-extracted with EtOAc. Organic phase was dried over anhydrous Na2SO4, filtrated 
with cotton wool and evaporated in vacuo with rotavapor and oil-pump. The product 
was purified with Biotage chromatography (Weak solvent: DCM + 2% TEA, Strong 
solvent: 9:1 DCM:MeOH). The solvent of combined tubes was evaporated in rotavapor 
and finally in oil-pump, but the 
1
H-NMR did not show any product assumed. 
 
3,5-Dibromo-4-hydroxybenzoic acid (62) 
 
Carboxylic acid 75 (2.00 g, 14.5 mmol, 1.0 eq) was dissolved in 50 ml of AcOH and 10 
ml H2O. After 10 minutes, bromine (2.60 ml, 50.8 mmol, 3.5 eq) was added dropwise. 
TLC (1:1 Hex:EtOAc) suggested completion of the reaction after 2 hr stirred at ambient 
room temperature. The product was filtered and the filtrate was washed water. The 
solvent residues were evaporated with oil-pump. White solid 3.36 g (78.3% yield). 
 
1
H-NMR (300 MHz, d6-DMSO) δ 8.01 (s, 2H). 
13
C-NMR (75 MHz, d6-DMSO) δ 
164.82, 154.72, 133.31, 124.58, 111.28. NMR-data is in accordance with literature 
(Spectral Database System of Organic Compounds 2015). 
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Methyl-3,5-dibromo-4-methoxybenzoate (76a), (76b) The reaction was done twice: 
 
76a: Carboxylic acid 62 (1.00 g, 3.40 mmol, 1.0 eq) and K2CO3 (0.93 g, 6.80 mmol, 2.0 
eq) were dissolved in DMF under argon atmosphere and MeI (2.11 ml, 33.8 mmol, 10.0 
eq) was added. TLC (9:1 DCM:MeOH) suggested completion of reaction after 3.5 hr. 
The product was extracted with EtOAc and washed with water. Organic phase was 
dried over anhydrous Na2SO4, filtrated with cotton wool and evaporated in vacuo with 
rotavapor and oil-pump, white powder 0.78 g (70.9% yield).  
 
76b: Carboxylic acid 62 (0.70 g, 2.37 mmol, 1.0 eq), K2CO3 (0.65 g, 4.73 mmol, 2.0 
eq), MeI (1.47 ml, 23.7 mmol, 10.0 eq) and DMF were added similarly. TLC (2:1 
Hex:Acetone + 2% TEA) suggested near completion of reaction after 2 hr. K2CO3 was 
filtered away with cotton wool. DMF was concentrated with rotavapor. Otherwise 
similar work-up gave white solid 0.57 g (74.8% yield).  
 
1
H-NMR (300 MHz, CDCl3) δ 8.18 (s, 2H), 3.94 (s, 3H), 3.91 (s, 3H). 
13
C-NMR (75 
MHz, CDCl3) δ 164.49, 158.17, 134.24, 128.47, 118.36, 60.90, 52.75. NMR-data is in 
accordance with literature (Grimster et al. 2013).  
 
3,5-Dibromo-4-methoxybenzoic acid (60a), (60b) The reaction was made in two 
separated times: 
 
60a: Methylated carboxylic acid 76a (0.78 g, 2.41 mmol, 1.0 eq) and lithium hydroxide 
monohydrate (0.25 g, 6.01 mmol, 2.5 eq) were dissolved in 1:1 H2O/THF solution. The 
reaction was first kept at ambient room temperature and eventually heated to 60 °C. 
After 24 hr TLC (1:1 Hex:EtOAc) indicated completion of reaction. 1 M HCl (10 ml) 
was added and the water phase was extracted with EtOAc. Organic phase was dried 
over anhydrous Na2SO4, filtrated with cotton wool and evaporated in vacuo with 
rotavapor. The rest of the solvents was evaporated with oil-pump. White solid 0.64 g 
(86.2% yield). 
 
60b: Methylated carboxylic acid 76b (0.57 g, 1.77 mmol, 1.0 eq) and Lithium 
hydroxide monohydrate (0.19 g, 4.43 g, 2.5 eq) were dissolved as earlier. The reaction 
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was left over weekend, TLC (8:2 Hex:EtOAc) indicated completion of reaction after 66 
hr. After similar work-up, white solid 0.48 g (87.2% yield).  
 
1
H-NMR (300 MHz, d6-DMSO) δ 13.45 (s, 1H), 8.10 (s, 2H), 3.87 (s, 3H). 
13
C-NMR 
(75 MHz, d6-DMSO) δ 164.44, 157.00, 133.54, 129.53, 117.65, 60.58, 39.52. 
 
3-Bromo-4-methoxybenzoic acid (61) 
 
Carboxylic acid 63 (0.50 g, 3.29 mmol, 1.0 eq) was dissolved in 10 ml AcOH and 2 ml 
water. Bromine (0.60 ml, 11.5 mmol, 3.5 eq) was added dropwise. The reaction was left 
over weekend. After 71 hr TLC (9:1 DCM:MeOH) indicated only one spot. The product 
was filtered while washing with Et2O, white solid 0.30 g (29.6% yield).  
 
1
H-NMR (300 MHz, d6-DMSO) δ 12.90 (s, 1H), 8.06 (d, J = 2.1 Hz, 1H), 7.94 (dd, J = 
2.1, 8.6 Hz, 1H), 7.21 (d, J =  8.7 Hz, 1H), 3.93 (s, 3H), 3.29 (s, 1H) HRMS (ESI+): 
Calculated value 230.9657 (C8H7BrO3), found value 230.9651. 
 
3-(Acetylthio)propanoic acid (72) 
 
Thiol acid 71 (10.0 ml, 115.0 mmol, 1.0 eq), 20 ml DCM and 30 ml AcOH were added 
into cooled argon atmosphere. Acetyl chloride (24.5 ml, 344.0 mmol, 3 eq) was added 
dropwise. The reaction was heated up to ambient room temperature. After 23 hr TLC 
indicated completion of reaction. The solvents were concentrated carefully in rotavapor. 
The product was purified with flash chromatography, used amount of silica was 300 ml 
(8:2 Hex:EtOAc). For better detection, the used TLC-plates from the tubes were colored 
with dinitrophenylhydrazine or bromocresol green. The combined solvents from tubes 
were evaporated carefully in rotavapor, clear solid 10.8 g (63.3% yield).  
 
1
H-NMR (300 MHz, CDCl3) δ 3.10 (t, J = 6.9 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H), 2.33 (s, 
3H). 
13
C-NMR (75 MHz, CDCl3) δ 195.60, 177.72, 34.29, 30.63, 23.96. NMR-data is in 
accordance with literature (Ekeroth et al. 2002).  
 
74 
 
 
9.3 Biological activity tests 
 
The compounds activity to EAG channels were tested by Prof Jan Tytgat, Toxicology 
and Pharmacology, Catholic University of Leuven, Belgium. Xenopus laevis frogs 
oocytes were used to study the expression of the voltage gated potassium channels 
(hKv1.3, hKv10.1). The linearized plasmids were transcribed using the T7 or SP6 
mMESSAGE-mMACHINE transcription kit (Ambion, USA). The stage V-VI oocytes 
were harvested from anasthetized female Xenopus laevis frog. The oocytes were 
Oocytes were injected with 50 nl of cRNA at a concentration of 1 ng/nl using a micro-
injector (Drummond Scientific, USA). The oocytes were incubated in a solution 
containing (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4), 
supplemented with 50 mg/l gentamycin sulfate. Two-electrode voltage-clamp 
recordings were performed at room temperature (18-22°C) using a Geneclamp 500 
amplifier (Molecular Devices, USA) controlled by a pClamp data acquisition system 
(Axon Instruments, USA). Whole cell currents from oocytes were recorded 1-4 days 
after injection. Bath solution composition was ND96 (in mM): NaCl, 96; KCl, 2; CaCl2, 
1.8; MgCl2, 2 and HEPES, 5 (pH 7.4) or HK (in mM): NaCl, 2; KCl, 96; CaCl2, 1.8; 
MgCl2, 2 and HEPES, 5 (pH 7.4). Voltage and current electrodes were filled with 3 M 
KCl. Resistances of both electrodes were kept between 0.7-1.5 MΩ. The elicited 
currents were filtered at 2 kHz and sampled at 500 Hz using a four-pole low-pass Bessel 
filter. Leak subtraction was performed using a -P/4 protocol. Kv1.3 currents were 
evoked by 500 ms depolarizations to 0 mV followed by a 500 ms pulse to -50 mV, from 
a holding potential of -90 mV. Current traces of Kv10.1 channels were elicited by 
applying a 0 mV pulse for 2 s from a holding potential of -90 mV. All data represent at 
least 3 independent experiments (n ≥ 3) and are presented as mean ± standard error. 
 
Compounds activity against hepatitis C virus (HCV) was screened in Päivi Tammela's 
group by Katja-Emilia Lillsunde, University of Helsinki. The antiviral screening was 
done with CV-Huh7 cell line that expresses HCV replicon and the Firefly luciferase as a 
reporter. Firefly luciferase produces light by catalysing luciferin oxidation using ATP 
and Mg2+ as a cosubstrate. The seeded 96-plate cells and samples were incubated 
overnight. The expression of the HCV replicon was measured after 24 hr incubation. 
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This was done by using Firefly luciferase (FFluc) assay kit from Promega (Luciferase 
Assay System) (WI, USA). The inhibition of the HCV replicon and the activity of the 
samples were calculated by comparing the luminescense with the DMSO vehicle 
control. Additionally, the used positive control was 60 µM 6-azauridine, that should 
show approx. 50% inhibition. Each sample was tested in triplicate, and the average 
inhibition and standard deviations were calculated.  
 
 
10 LITERATURE 
 
Atanassoff PG, Hartmannsgruber MWB, Thrasher J, Wermeling D, Longton W, Gaeta 
R, Singh T, Mayo M, McGuire D, Luther RR: Ziconotide, a new N-type calcium 
channel blocker, administered intrathecally for acute postoperative pain. Reg. Anesth. 
Pain Med. 25: 274-278, 2000 
 
Badr JM, Shaala LA, Abou-Shoer MI, Tawfik MK, Habib A-M: Bioactive brominated 
metabolites from the red sea sponge Pseudoceratina arabica. J. Nat. Prod. 71: 1472-
1474, 2008 
 
Bergquist PR: Dictryoceratida, dendroceratida and Verondiga from the new caledonia 
lagoon (Porifera: Demonspongiae). Memoirs of the Queensland Museum 38: 1-51, 1995 
 
Bergquist PR, Cook SC: Family Pseudoceratinidae Carter, 1885. In book: Systema 
Porifera: A Guide to the Classification of Sponges. p. 1086-1088. Edited by Hooper J 
and Rob WM, Springer New York 2002 
 
Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR: Marine natural products. 
Nat. Prod. Rep. 31: 160-258, 2014 
 
Borchiellini C, Manuel M, Alivon E, Boury-Esnault N, Vacelet J, Le Parco Y: Sponge 
paraphyly and the origin of Metazoa. J. Evol. Biol. 14: 171-179, 2001 
 
Branchek TA and Blackburn TP: Trace amine receptors as targets for novel 
therapeutics: Legend, myth and fact. Curr. Opin. Pharmacol. 3: 90-97, 2003 
 
Costantino V, Fattorusso E, Mangoni A, Pansini M: Three new brominated and 
iodinated tyrosine derivatives from iotrochota birotulata, a non-Verongida sponge. J. 
Nat. Prod. 57: 1552-1556, 1994 
 
Cragg GM and Newman DJ: Natural products: A continuing source of novel drug leads. 
Biochim. Biophys. Acta, Gen. Subj. 1830: 3670-3695, 2013 
 
Cragg GM, Katz F, Newman DJ, Rosental J: Legal and ethical issues involving marine 
biodiscovery and development. In book: Handbook of Marine Natural Products. p. 
76 
 
 
1314-1342. Edited by Fattorusso E, Gerwick WH, Taglialatela-Scafati O, Springer 
Science+Business Media B.V., Dordrecht, 2012 
 
Crosslinking Reagents Technical Handbook 2012. Referred 5.4.2015. The link to the 
PDF available from internet: https://www.lifetechnologies.com/fi/en/home/life-
science/protein-biology/protein-biology-learning-center/protein-biology-resource-
library/pierce-protein-methods/chemistry-crosslinking.html 
 
Doherty MK and Morris PG: Eribulin for the treatment of metastatic breast cancer: An 
update on its safety and efficacy. Int. J. Women's Health 7: 47-58, 2015 
 
Duodecim: Lääkärin tietokannat (online). Referred 18.4.2015. Available online: 
http://www.terveysportti.fi.libproxy.helsinki.fi/dtk/ltk/koti?p_artikkeli=ykt00261&p_ha
ku=c-hepatiitti 
 
Ekeroth J, Borgh A, Konradsson P, Liedberg B: Synthesis and monolayer 
characterization of phosphorylated amino acid analogs. J. Colloid Interface Sci. 254: 
322-330, 2002 
 
Evan T, Rudi A, Ilan M, Kashman Y: Aplyzanzine A, a new dibromotyrosine derivative 
from a Verongida sponge. J. Nat. Prod. 64: 226-227, 2001 
 
Flemmich Paul: Master's thesis. University of Helsinki, to be published 2015 
 
Fujiwara T, Hwang J-, Kanamoto A, Nagai H, Takagi M, Shin-Ya K: JBIR-44, a new 
bromotyrosine compound from a marine sponge Psammaplysilla purpurea. J. Antibiot. 
62: 393-395, 2009 
 
Gerwick WH and Moore BS: Lessons from the past and charting the future of marine 
natural products drug discovery and chemical biology. Chemistry and Biology 19: 85-
98, 2012 
 
Gotsbacher MP and Karuso P: New antimicrobial bromotyrosine analogues from the 
sponge Pseudoceratina purpurea and its predator Tylodina corticalis. Mar. Drugs 13: 
1389-1409, 2015 
 
Grimster NP, Connelly S, Baranczak A, Dong J, Krasnova LB, Sharpless KB, Powers 
ET, Wilson IA, Kelly JW: Aromatic sulfonyl fluorides covalently kinetically stabilize 
transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate. J. Am. 
Chem. Soc. 135: 5656-5668, 2013 
 
Hamman MT, Scheuer PJ, Kelly-Borges M: Biogenetically diverse, bioactive 
constituents of a sponge, order Verongida: Bromotyramines and sesquiterpene-
Shikimate derived metabolites. J. Org. Chem. 58: 6565-6569, 1993 
 
Harburn JJ, Rath NP, Spilling CD: Efficient synthesis of tyrosine-derived marine 
sponge metabolites via acylation of amines with a coumarin. J. Org. Chem. 70: 6398-
6403, 2005 
77 
 
 
Hauptmann N, Grimsby J, Shih JC, Cadenas E: The metabolism of tyramine by 
monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch. 
Biochem. Biophys. 335: 295-304, 1996 
 
Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. 
Biochem. Biophys. Res. Commun. 249: 838-843, 1998 
 
Isobe T and Ishikawa T: 2-Chloro-1,3-dimethylimidazolinium chloride. 1. A powerful 
dehydrating equivalent to DCC. J. Org. Chem. 64: 6984-6988, 1999 
 
Jung JH, Sim CJ, Lee C: Cytotoxic compounds from a two-sponge association. J. Nat. 
Prod. 58: 1722-1726, 1995 
 
Jurek J, Yoshida WY, Scheuer PJ, Kelly-Borges M: Three new bromotyrosine-derived 
metabolites of the sponge Psammaplysilla purpurea. J. Nat. Prod. 56: 1609-1612, 1993 
 
Kanagasabhapathy M and Nagata S: Cross-species induction of antibacterial activity 
produced by epibiotic bacteria isolated from Indian marine sponge Pseudoceratina 
purpurea. World J. Microbiol. Biotechnol. 24: 687-691, 2008 
 
Kang J, Miyajima D, Itoh Y, Mori T, Tanaka H, Yamauchi M, Inoue Y, Harada S, Aida 
T: C5 - Symmetric chiral corannulenes: Desymmetrization of bowl inversion 
equilibrium via "intramolecular" hydrogen-bonding network. J. Am. Chem. Soc. 136: 
10640-10644, 2014 
 
Kennedy JP, Brogan JT, Lindsley CW: Total synthesis and biological evaluation of the 
marine bromopyrrole alkaloid dispyrin: Elucidation of discrete molecular targets with 
therapeutic potential. J. Nat. Prod. 71: 1783-1786, 2008 
 
Kennedy JP, Jeffrey Conn P, Lindsley CW: A novel class of H3 antagonists derived 
from the natural product guided synthesis of unnatural analogs of the marine 
bromopyrrole alkaloid dispyrin. Bioorg. Med. Chem. Lett. 19: 3204-3208, 2009 
 
Kim D, Lee IS, Jung JH, Yang S: Psammaplin A, a natural bromotyrosine derivative 
from a sponge, possesses the antibacterial activity against methicillin-resistant 
Staphylococcus aureus and the DNA gyrase-inhibitory activity. Arch. Pharm. Res. 22: 
25-29, 1999 
 
Kobayashi J, Honma K, Sasaki T, Tsuda M: Purealidins J-R, new bromotyrosine 
alkaloids from the okinawan marine sponge Psammaplysilla purea. Chem. Pharm. Bull. 
43: 403-407, 1995 
 
Koski RR: Omega-3-acid ethyl esters (Lovaza) for severe hypertriglyceridemia. P&T 
33: 271-273, 2008 
 
Kotoku N, Tsujita H, Hiramatsu A, Mori C, Koizumi N, Kobayashi M: Efficient total 
synthesis of bastadin 6, an anti-angiogenic brominated tyrosine-derived metabolite from 
marine sponge. Tetrahedron 61: 7211-7218, 2005 
78 
 
 
Kottakota SK, Evangelopoulos D, Alnimr A, Bhakta S, McHugh TD, Gray M, 
Groundwater PW, Marrs ECL, Perry JD, Spilling CD, Harburn JJ: Synthesis and 
biological evaluation of purpurealidin E-derived marine sponge metabolites: 
Aplysamine-2, Aplyzanzine A, and Suberedamines A and B. J. Nat. Prod. 75: 1090-
1101, 2012 
 
Ladero V, Fernández M, Alvarez MA: Isolation and identification of tyramine-
producing enterococci from human fecal samples. Can. J. Microbiol. 55: 215-218, 2009 
 
Larsson R and Ramström O: Dynamic combinatorial thiolester libraries for efficient 
catalytic self-screening of hydrolase substrates. Eur. J. Org. Chem. 285-291, 2006 
 
Leino R and Lönnqvist J-: A very simple method for the preparation of symmetrical 
disulfides. Tetrahedron Lett. 45: 8489-8491, 2004 
 
Leino Teppo: Clathrodin analogs as voltage-gated sodium channel blockers. Master's 
thesis. University of Helsinki, 2013 
 
Leys SP and Hill A: The Physiology and Molecular Biology of Sponge Tissues. Adv. 
Mar. Biol. 62: 1-56, 2012 
 
Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC: Trace 
amine-associated receptors form structurally and functionally distinct subfamilies of 
novel G protein-coupled receptors. Genomics 85: 372-385, 2005 
 
Mahindroo N, Connelly MC, Punchihewa C, Kimura H, Smeltzer MP, Wu S, Fujii N: 
Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of 
glioma-associated oncogene homologue 1 (Gli1) mediated transcription. J. Med. Chem. 
52: 4277-4287, 2009 
 
MAREX project (online). Referred 7.4.2015. Available from internet: 
http://www.marex.fi/project-description 
 
Mayer AMS, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, 
Newman DJ, Potts BC, Shuster DE: The odyssey of marine pharmaceuticals: a current 
pipeline perspective. Trends Pharmacol. Sci. 31: 255-265, 2010 
 
Mayer AMS, Rodríguez AD, Taglialatela-Scafati O, Fusetani N: Marine pharmacology 
in 2009-2011: Marine compounds with antibacterial, antidiabetic, antifungal, anti-
inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the 
immune and nervous systems, and other miscellaneous mechanisms of action. Mar. 
Drugs 112510-2573, 2013  
 
Mayer AMS: Marine Pharmacology (online). Site updated June 2014. Referred 
27.02.2015. Available from internet: 
http://marinepharmacology.midwestern.edu/clinPipeline.htm 
 
79 
 
 
Molinski TF, Dalisay DS, Lievens SL, Saludes JP: Drug development from marine 
natural products. Nat. Rev. Drug Discovery 8: 69-85, 2009 
 
Morkunas B, Galloway WRJD, Wright M, Ibbeson BM, Hodgkinson JT, O'Connell 
KMG, Bartolucci N, Valle MD, Welch M, Spring DR: Inhibition of the production of 
the Pseudomonas aeruginosa virulence factor pyocyanin in wild-type cells by quorum 
sensing autoinducer-Mimics. Org. Biomol. Chem. 10: 8452-8464, 2012 
 
Neises B and Steglich W: Simple Method for the esterification of carboxylic acids. 
Angew. Chem. Int. 17: 522–524, 1978 
 
Newman DJ and Cragg GM: Natural products as sources of new drugs over the 30 years 
from 1981 to 2010. J. Nat. Prod. 75: 311-335, 2012 
 
Park Y, Liu Y, Hong J, Lee C, Cho H, Kim D, Im KS, Jung JH: New bromotyrosine 
derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra 
wondoensis. J. Nat. Prod. 66: 1495-1498, 2003 
 
Peng J, Li J, Hamann MT: The Marine Bromotyrosine Derivatives. Alkaloids: 
Chemistry and Biology 61: 59-262, 2005 
 
Petek BJ, Loggers ET, Pollack SM, Jones RL: Trabectedin in soft tissue sarcomas. Mar. 
Drugs 13: 974-983, 2015 
 
Piña IC, White KN, Cabrera G, Rivero E, Crews P: Bromopyrrole carboxamide 
biosynthetic products from the Caribbean sponge Agelas dispar. J. Nat. Prod. 70: 613-
617, 2007 
 
Rama Rao M, Venkatesham U, Venkateswarlu Y: Two bromo compounds from the 
sponge Psammaplysilla purpurea. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. 
Chem. 38: 1301-1303, 1999 
 
Schoenfeld RC and Ganem B: Synthesis of ceratinamine and moloka'iamine: 
Antifouling agents from the marine sponge Pseudoceratina purpurea. Tetrahedron Lett. 
39: 4147-4150, 1998 
 
Schoenfeld RC, Conova S, Rittschof D, Ganem B: Cytotoxic, antifouling 
bromotyramines: A synthetic study on simple marine natural products and their 
analogues. Bioorg. Med. Chem. Lett. 12: 823-825, 2002 
 
Shulman KI, Herrmann N, Walker SE: Current place of monoamine oxidase inhibitors 
in the treatment of depression. CNS Drugs 27: 789-797, 2013 
 
Skropeta D and Wei L: Recent advances in deep-sea natural products. Nat. Prod. Rep. 
31: 999-1025, 2014 
 
Spectral Database System of Organic Compounds (online). Referred 16.03.2015. Data 
is obtained from the National Institute of Advanced Industrial Science and Technology, 
80 
 
 
AIST (Japan). Available from internet: http://sdbs.db.aist.go.jp/sdbs/cgi-
bin/cre_index.cgi. 
 
Taylor MW, Radax R, Steger D, Wagner M: Sponge-associated microorganisms: 
Evolution, ecology, and biotechnological potential. Microbiol. Mol. Biol. Rev. 71: 295-
347, 2007 
 
Tilvi S and D'Souza L: Identifying the related compounds using electrospray ionization 
tandem mass spectrometry: bromotyrosine alkaloids from marine sponge 
Psammaplysilla purpurea.  Eur. J. Mass Spectrom. 18: 333-343, 2012 
 
Tilvi S, Rodrigues C, Naik CG, Parameswaran PS, Wahidhulla S: New bromotyrosine 
alkaloids from the marine sponge Psammaplysilla purpurea. Tetrahedron 60: 10207-
10215, 2004 
 
Tsuda M, Sakuma Y, Kobayashi J: Suberedamines A and B, new bromotyrosine 
alkaloids from a sponge Suberea species. J. Nat. Prod. 64: 980-982, 2001 
 
Tsukamoto S, Kato H, Hirota H, Fusetani N: Ceratinamine: An unprecedented 
antifouling cyanoformamide from the marine sponge Pseudoceratina purpurea. J. Org. 
Chem. 61: 2936-2937, 1996 
 
Wada Y, Harayama Y, Kamimura D, Yoshida M, Shibata T, Fujiwara K, Morimoto K, 
Fujioka H, Kita Y: The synthetic and biological studies of discorhabdins and related 
compounds. Org. Biomol. Chem. 9: 4959-4976, 2011 
 
Venkateswarlu Y, Rama Rao M, Venkatesham U: A new dibromotyrosine-derived 
metabolite from the sponge Psammaplysilla purpurea. J. Nat. Prod. 61: 1388-1389, 
1998 
 
Wilkinson CR, Garrone R, Vacelet J: Marine sponges discriminate between food 
bacteria and bacterial symbionts: Electron microscope radioautography and in situ 
evidence. Proc. R. Soc. London, Ser. B 220: 519-528, 1984 
 
World porifera database (online). Referred 30.3.2015. Available from internet: 
http://www.marinespecies.org/porifera/porifera.php?p=taxdetails&id=169702 
 
Wright AE, Roth GP, Hoffman JK, Divlianska DB, Pechter D, Sennett SH, Guzmán 
EA, Linley P, McCarthy PJ, Pitts TP, Pomponi SA, Reed JK: Isolation, synthesis, and 
biological activity of aphrocallistin, an adenine-substituted bromotyramine metabolite 
from the hexactinellida sponge Aphrocallistes beatrix. J. Nat. Prod. 72: 1178-1183, 
2009 
 
Yoshida M and Yamaguchi K: Total synthesis of dispyrin, purpurealidin E, and 
aplysamine-1. Chem. Pharm. Bull. 56: 1362-1363, 2008 
 
Yoshida M and Yamaguchi K: Total synthesis of the marine bromotyrosine alkaloid 
moloka'iakitamide. Chem. Pharm. Bull. 57: 1147-1149, 2009 
81 
 
 
Younes A, Yasothan U, Kirkpatrick P: Brentuximab vedotin. Nat. Rev. Drug Discovery 
11: 19-20, 2012 
